BioXCell
Bio X Cell社ウェブサイト
Stay Connected
Bio X Cell社(アメリカ)の目標は、高品質な抗体を安価な価格で供給し、優れたカスタマーサービスを提供することで、科学的な発見やイノベーションの前進を促すことです。そのために同社は、in vivoの前臨床試験に必要とされる超高純度かつ防腐剤・安定剤不使用で低エンドトキシの抗体を、既知の抗原と新規性の高い抗原に対して多数取り揃えています。
Bio X Cell社の抗体は：
低エンドトキシン｜保存料およびキャリアタンパク質不使用｜マウス病原体スクリーニング済み(InVivoPlus)｜タンパク凝集物≤5%
弊社はBio X Cell社の正規代理店です。
大学および公的機関のお客様にはアカデミックディスカウントが適用されますので、お問い合わせください。
トピックス
Chemokine Axis Targets for In Vivo Research
Essential Isotype Controls
Achieve precise results with negative controls that distinguish true signal from background.
- ・Ultra-pure and low endotoxin
- ・Preservative- and stabilizer-free
- ・Ready for in vivo use
- ・InVivoMAb™, InVivoPlus™ and RecombiMAb formats available
Find your matched isotype control
InVivoPure™ Dilution Buffers
Engineered for in vivo and advanced models, delivering the highest quality standards.
- ・Ultra-pure and low endotoxin
- ・Pathogen-screened
- ・Safety tested in animal models
- ・Optimized composition and pH for Bio X Cell antibodies
Built for Reproducible Cancer Research
Functional antibodies for translational tumor biology
Bio X Cell functional antibodies are designed for in vivo cancer research, with ultrapure,
carrier-free formulations and ultra-low endotoxin levels to support clean, reproducible immune
modulation in tumor models.
Why Functional Antibodies Matter in Cancer Studies
- ・tumor biology: ultra-low endotoxin minimizes cytokine artifacts
- ・Perform in living systems: validated for functional activity in vivo
- ・Deliver consistent results: across tumor models and study designs
- ・Trusted at scale: nearly 30,000 peer-reviewed citations
Explore Antibodies for Cancer Research
Antibodies in Action
InVivoMAb anti-mouse CD73
Investigate how CD73-driven adenosine signaling suppresses anti-tumor immunity in the tumor
microenvironment. Browse CD73 antibodies for reproducible studies of immune suppression and tumor
biology.
Bispecific and Immune Activation Targets Featured This Week
Essential Isotype Controls
Achieve precise results with negative controls that distinguish true signal from background.
- ・Ultra-pure and low endotoxin
- ・Preservative- and stabilizer-free
- ・Ready for in vivo use
- ・InVivoMAb™, InVivoPlus™ and RecombiMAb formats available
Find your matched isotype control
InVivoPure™ Dilution Buffers
Engineered for in vivo and advanced models, delivering the highest quality standards.
- ・Ultra-pure and low endotoxin
- ・Pathogen-screened
- ・Safety tested in animal models
- ・Optimized composition and pH for Bio X Cell antibodies
Accelerating Brain Organoid Research
Insights from Experts
Dr. Debby Silver, Professor in the Departments of Molecular Genetics & Microbiology, Cell
Biology, and Neurobiology at Duke University School of Medicine, highlights how brain organoid models
enable investigation of human neurodevelopmental processes that traditional animal models cannot capture
alone. These 3D cultures strengthen experimental design and improve confidence in biological
interpretation.
Key takeaways:
- ・Organoids preserve human-relevant biology in 3D
- ・Brain organoids unlock human-specific neurodevelopment insights
- ・Used alongside animals, organoids strengthen translation
Antibodies in Action
InVivoMAb anti-mouse PD-1 (CD279)
InVivoMAb™ anti-mouse PD-1 helps reveal when and why T cells can regain tumor-killing
activity against PD-L1+ organoids. Browse PD-1 antibodies validated for organoid-based immunology
studies.
New from Bio X Cell
Demonstrating Consistent Antibody Performance Across In Vivo and Organoid Models
Bio X Cell announces new peer-reviewed findings demonstrating that its functional antibodies
maintain consistent performance across both murine in vivo models and human-relevant organoid systems,
enabling researchers to use the same reagents across experimental platforms without reformulation.
Trending Antibody Targets
CD73 Antibodies
Cancer Research
Immune checkpoint or co-stimulatory pathway target frequently used in cancer
immunotherapy.
VEGF-A Antibodies
Cancer Research
Tumor-associated antigen or oncology pathway commonly targeted in solid tumors.
CTLA-4 Antibodies
Cancer Research
Immune checkpoint or co-stimulatory pathway target frequently used in cancer
immunotherapy.
Bio X Cell Appoints ProBioscience Technologies as Distributor Across Southeast Asia
By partnering with ProBioscience, Bio X Cell expands its distribution footprint across the
growing research immunology and cancer communities in Singapore, Malaysia, Thailand, Vietnam, and
Indonesia. ProBioscience Technologies will provide direct, local access to the full Bio X Cell portfolio
which features ultrapure, low-endotoxin functional antibodies, formulated for in vivo studies.
Recent from Bio X Cell
Checkpoint Blockade, Escape and Beyond in Cancer Immune Modulation
In this webinar, Dr. Gordon Freeman explores how PD‑1 blockade antibodies are used to
interrogate immune checkpoint biology and model therapeutic mechanisms in preclinical systems.
Signal or Noise? Decoding in vivo CAR-T
In vivo CAR-T research is advancing rapidly, making biological signal clarity
increasingly important for translational insight. Learn how researchers are approaching
interpretability in in vivo CAR-T studies.
Announcing Bio X Cell’s Organoid-Validated Functional Antibodies
Bio X Cell Advances Translational Continuity with Organoid-Validated Functional Antibodies
Bio X Cell has announced new peer-reviewed evidence demonstrating consistent antibody performance across
murine in vivo models and human-relevant organoid systems, using the same functional antibody without
reformulation.
Ultrapure, carrier-free formulations with low endotoxin levels minimize cytokine artifacts in
sensitive 3D cultures, enabling reproducible blocking, depletion, activation, and neutralization across
systems.
“Using the same antibody across in vivo and organoid models helps researchers reduce
variability and supports more consistent interpretation of results across studies,” said Christopher
Conway, CEO of Bio X Cell.
In support of advancing reproducibility science, Bio X Cell is sponsoring the 2026 Reproducibility in Science Symposium hosted by Frederick National
Laboratory for Cancer Research in partnership with Hood College. Bio X Cell will present a scientific
poster highlighting its scalable recombinant antibody production platform for reproducible preclinical
research.
よくある質問
抗マウスCD16/CD32 Fc受容体阻害抗体
生体内実験のためのアイソタイプコントロールの選択と使用
RecombiMAb™：in vivo用途のためのリコンビナント抗体
抗PD-1抗体の選び方 HOT
PD-1およびPD-L1マウスモノクローナル抗体の比較 HOT
抗SARS-CoV-2スパイクタンパク質抗体のご紹介
in vivoでのB細胞の枯渇を目的とした抗マウスCD20抗体
免疫チェックポイント関連商品
生体実験のためのマウス免疫細胞枯渇抗体
抗体の構造
Bio X Cell社製品を用いた研究のご紹介
ウイルス感染の間、TIGITは免疫病変(immunopathology)を制限します
乳癌の転移を阻止する：カテプシンC阻害剤の役割
Cold TumorをHotに変える:乳がんに対する免疫の調節因子としてのRANK経路
LinkRNA EPIC1が免疫療法耐性獲得を仲介する
アルツハイマー病におけるApoE4毒性の新規モデル
COVID-19の発症と治療の新規モデル
腸内細菌叢を介した鎌状赤血球症とストレスのつながり
動き回るマクロファージ：肺胞マクロファージのパトロールの可視化
粘膜微小環境の問題―ウイルス素因における好中球性炎症の役割
新規チェックポイント阻害剤の抗NKG2A抗体は、T細胞およびNK細胞の両方の抗腫瘍免疫応答を促進する作用を持つ
微生物感染は自己免疫応答を誘導する
抗CD47抗体は循環器疾患の予防に有効である
免疫チェックポイント分子LAG-3に対する新たなリガンドFGL1の発見と、FGL1阻害によるT細胞の抗腫瘍免疫応答の可能性
癌の肺転移においてT細胞の酸素感知が果たす役割
悪性黒色腫はIFNγ変異を起こすことにより抗CTLA-4免疫療法に対抗する
ILC2に発現しているGITRの活性化は2型糖尿病を改善する
TNF阻害剤による予防的治療は多併用免疫療法の転帰を改善する可能性がある
がん免疫療法に最適化されたアゴニスト活性をもつ抗4-1BB抗体の探究
新着情報
2024.12.24更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0442 | InVivoMAb anti-rat CD86 (B7-2) | OX-48 |
| BE0443 | InVivoMAb anti-mouse PDGFRα (CD140a) | APA5 |
| BE0444 | InVivoMAb anti-human/mouse/rat/canine/swine PSMA | 3F11 |
| BE0445 | InVivoMAb anti-mouse CD44 | KM703 |
| BE0446 | InVivoMAb anti-rat CD47 | OX-101 |
| BE0447 | InVivoMAb anti-mouse TREM-2 | 178 |
| BE0448 | InVivoMAb anti-rat CD90/mouse CD90.1 (Thy1.1) | OX-7 |
| BE0449 | InVivoMAb anti-mouse CCL5 (RANTES) | R6G9 |
| BE0450 | InVivoMAb anti-mouse CXCL16 (SR-PSOX) | 12-81 |
| CP178 | RecombiMAb anti-mouse PD-1 (CD279) | 29F.1A12™-CP178 |
| CP182 | RecombiMAb anti-mouse PD-1 (CD279) | RMP1-14-CP182 |
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | N/A |
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | N/A |
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | N/A |
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | N/A |
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | N/A |
| SIM0039 | InVivoSIM anti-human CEACAM5 (Labetuzumab Biosimilar) | Labetuzumab |
| SIM0040 | InVivoSIM anti-human mesothelin (Amatuximab Biosimilar) | Amatuximab |
| SIM0041 | InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar) | Elotuzumab |
| SIM0042 | InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar) | Tralokinumab |
| SIM0043 | InVivoSIM anti-human TIM-3 (Sabatolimab Biosimilar) | Sabatolimab |
| SIM0044 | InVivoSIM anti-human IL-1β (Canakinumab Biosimilar) | Canakinumab |
| SIM0045 | InVivoSIM anti-human CD326 (EpCAM) (Edrecolomab Biosimilar) | Edrecolomab |
| SIM0046 | InVivoSIM anti-human CTLA-4 (Tremelimumab Biosimilar) | Tremelimumab |
| SIM0047 | InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar) | Solanezumab |
| SIM0048 | InVivoSIM anti-human amyloid beta (Donanemab Biosimilar) | Donanemab |
| SIM0049 | InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar) | Gevokizumab |
| SIM0050 | InVivoSIM anti-human EGFR (Panitumumab Biosimilar) | Panitumumab |
| SIM0051 | InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar) | Sacituzumab |
PD-1とPD-L1の結合を阻害するRecombiMAb anti-mouse PD-1 (CD279)
新商品のリコンビナント抗マウスPD-1(CD279)抗体(RMP1-14クローン)は、PD-1とそのリガンドであるPD-L1、PD-L2の結合を阻害するブロッキング抗体として機能します。RMP1-14クローンは、がんや自己免疫疾患のマウスモデルにおけるPD-1の機能の研究に特に有用です。マウスのPD-1を特異的にターゲティングし、様々な前臨床モデルで強力な抗腫瘍活性を示します。
2024.05.30更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0423 | InVivoMAb anti-mouse VISTA | 8G8 |
| BE0424 | InVivoMAb anti-rat CTLA-4 (CD152) | WKH203 |
| BE0425 | InVivoMAb rat IgG2b isotype control, anti-trinitrophenol-keyhole limpet hemocyanin | TNP-4G1 |
| BE0426 | InVivoMAb anti-mouse Dendritic Cell Marker (33D1) | 33D1 |
| BE0427 | InVivoMAb anti-West Nile virus NS1 | 10NS1 |
| BE0428 | InVivoMAb anti-mouse CD11b | 5C6 |
| BE0429 | InVivoMAb anti-WNV E protein DIII-LR | E16 |
| BE0430 | InVivoMAb anti-WNV E protein DI-DII | E53 |
| BE0431 | InVivoMAb anti-Zika virus E protein DIII-LR | ZV-67 |
| BE0432 | InVivoMAb anti-Dengue virus type 2 E protein DIII | DV2-96 |
| BE0433 | InVivoMAb anti-Eastern equine encephalitis virus E2 protein | EEEV-3 |
| BE0434 | InVivoMAb anti-Powassan virus E protein | POWV-63 |
| BE0435 | InVivoMAb anti-Venezuelan equine encephalitis virus E2 protein | VEEV-57 |
| BE0436 | InVivoMAb anti-human VISTA | GG8 |
| BE0437 | InVivoMAb anti-Dengue virus type 4 E protein DIII | DV4-E88 |
| BE0438 | InVivoMAb anti-SARS-CoV-2 S protein (RBD) | SARS2-38 |
| BE0439 | InVivoMAb anti-rat CD4 | W3/25 |
| CP158 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 10F.9G2™-CP158 |
| SIM0033 | InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) | Tiragolumab |
| SIM0034 | InVivoSIM anti-human CD38 (Daratumumab Biosimilar) | Daratumumab |
2024.03.22更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0415 | InVivoMAb anti-rat CD8α | OX-8 |
| BE0416 | InVivoMAb anti-human/mouse GRP78 | N88 |
| BE0417 | InVivoMAb anti-rat CD2 | OX-34 |
| BE0418 | InVivoMAb anti-rat CD28 | JJ316 |
| BE0419 | InVivoMAb anti-rat IL-4 | OX-81 |
| BE0420 | InVivoMAb anti-mouse CD205 (DEC-205) | NLDC-145 |
| BE0421 | InVivoMAb anti-chikungunya virus E2 | CHK-265 |
| BE0422 | InVivoMAb anti-mouse CD86 (B7-2) | 2D10 |
| CP172 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5-CP172 |
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | N/A |
| SIM0032 | InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) | Lecanemab |
BioXCell社の抗体は、国内外の大学、製薬企業等で幅広くご使用いただいております。
商品詳細や価格等は東京未来スタイルまでお問い合わせください。
| ランク | カタログ番号 | クローン | 商品名 |
|---|---|---|---|
| 1 | BE0146 | RMP1-14 | InVivoMab anti-mouse PD-1 (CD279) |
| 2 | BE0089 | 2A3 | InVivoMab rat IgG2a isotype control, anti-trinitrophenol |
| 3 | BP0146 | RMP1-14 | InVivoPlus anti-mouse PD-1 (CD279) |
| 4 | BE0101 | 10F.9G2 | InVivoMab anti-mouse PD-L1 (B7-H1) |
| 5 | BE0090 | LTF-2 | InVivoMab rat IgG2b isotype control, anti-keyhole limpet hemocyanin |
| 6 | BP0089 | 2A3 | InVivoPlus anti-mouse CTLA-4 (CD152) |
| 7 | BE0003-1 | GK1.5 | InVivoMab anti-mouse CD4 |
| 8 | BE0131 | 9H10 | InVivoMab anti-mouse CTLA-4 (CD152) |
| 9 | BP0101 | 10F.9G2 | InVivoPlus anti-mouse PD-L1 (B7-H1) |
| 10 | BE0083 | MOPC-21 | InVivoMab mouse IgG1 isotype control, unknown specificity |
| 11 | BE0273 | 29F.1A12 | InVivoMab anti-mouse PD-1 (CD279) |
| 12 | BE0164 | 9D9 | InVivoMab anti-mouse CTLA-4 (CD152) |
| 13 | BE0061 | 2.43 | InVivoMab anti-mouse CD8α |
| 14 | BE0088 | HRPN | InVivoMab rat IgG1 isotype control, anti-horseradish peroxidase |
| 15 | BP0083 | MOPC-21 | InVivoPlus mouse IgG1 isotype control, unknown specificity |
| 16 | BE0213 | AFS98 | InVivoMab anti-mouse CSF1R (CD115) |
| 17 | BE0036 | PK136 | InVivoMab anti-mouse NK1.1 |
| 18 | BP0164 | 9D9 | InVivoPlus anti-mouse CTLA-4 (CD152) |
| 19 | BE0085 | C1.18.4 | InVivoMab mouse IgG2a isotype control, unknown specificity |
| 20 | BP0090 | LTF-2 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin |
InVivoMabとInVivoPlusの違いについて
| InVivoMab | InVivoPlus | |
| 純度 | >95% | >95% |
| タンパクの完全性 | SDS-PAGE検証済み | SDS-PAGE検証済み |
| エンドトキシン | <2EU/mg | <1EU/mg |
| WB/FC/ELISAによる検証 | 未検証 | 検証済み |
| タンパク凝集物≤5% | 未検証 | 検証済み |
| マウス病原体スクリーニング | 未検証 | 検証済み |
| 保存料およびキャリアタンパク質 | 不使用 | 不使用 |
| バルク容量対応 | 対応可能 | 対応可能 |
| in vivo試験での使用 | 使用可能 | 使用可能 |
| カタログ番号 | BEから | BPから |
商品リスト
-
in vivo用途向けに設計された抗体製品
-
InVivoMabより厳しいQCを受けた高品質抗体
-
アイソタイプコントロール
-
In vivoで利用できるタグ検出用の抗体
-
In vivo用途向きの厳密な検査を通過した緩衝液
-
抗体医薬品研究用のバイオシミラー
-
マウスやヒト化マウスでの免疫原性を抑えられるリコンビナント抗体
InVivoMab
研究分野
ターゲット
| BE0000 | InVivoMAb anti-mouse CD1d (CD1.1) | 1/5/25/50/100 mg | |||||
| Clone | 19G11 | Isotype | Rat IgG1 | ||||
| Application | in vivo CD1d neutralization, in vitro CD1d neutralization | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0001-1FAB | InVivoMAb anti-mouse CD3ε F(ab')2 fragment | 5/10/25/50 mg | |||||
| Clone | 145-2C11 f(ab')2 Fragments | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo T cell depletion | ||||||
| Recommended | Isotype Control: BE0091-FAB Dilution Buffer: IP0070 | ||||||
| BE0001-1 | InVivoMAb anti-mouse CD3ε | 1/5/25/50/100 mg | |||||
| Clone | 145-2C11 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0001-2 | InVivoMAb anti-human CD3 | 1/5/25/50/100 mg | |||||
| Clone | OKT-3 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vitro T cell stimulation/activation, in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenografts, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0002 | InVivoMAb anti-mouse CD3 | 1/5/25/50/100 mg | |||||
| Clone | 17A2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vitro T cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0003-1 | InVivoMAb anti-mouse CD4 | 1/5/25/50/100 mg | |||||
| Clone | GK1.5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0065 | ||||||
| BE0003-2 | InVivoMAb anti-human CD4 | 1/5/25/50/100 mg | |||||
| Clone | OKT-4 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vitro T cell stimulation/activation, in vivo CD4+ T cell depletion in humanized mice, Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0003-3 | InVivoMAb anti-mouse CD4 | 1/5/25/50/100 mg | |||||
| Clone | YTS 177 | Isotype | Rat IgG2a | ||||
| Application | in vivo blockade of CD4+ T-cell responses, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0004-1 | InVivoMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | 53-6.7 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0065 | ||||||
| BE0004-2 | InVivoMAb anti-human CD8α | 1/5/25/50/100 mg | |||||
| Clone | OKT-8 | Isotype | Mouse IgG2a | ||||
| Application | in vivo CD8+ T cell depletion in humanized mice | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IPT060 | ||||||
| BE0005-1 | InVivoMAb anti-mouse LFA-1α (CD11a) | 1/5/25/50/100 mg | |||||
| Clone | FD441.8 | Isotype | Rat IgG2b | ||||
| Application | in vivo LFA-1 neutralization | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0005 | InVivoMAb anti-human LFA-1α (CD11a) | 1/5/25/50/100 mg | |||||
| Clone | TS-1/22.1.1.13 | Isotype | Mouse IgG1 | ||||
| Application | in vitro LFA-1 neutralization | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0006 | InVivoMAb anti-mouse LFA-1α (CD11a) | 1/5/25/50/100 mg | |||||
| Clone | M17/4 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo LFA-1 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0007 | InVivoMAb anti-mouse/human CD11b | 1/5/25/50/100 mg | |||||
| Clone | M1/70 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD11b neutralization, ILC2 cell purification, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0009 | InVivoMAb anti-mouse CD18 | 1/5/25/50/100 mg | |||||
| Clone | M18/2 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo LFA-1 neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0011 | InVivoMAb anti-mouse CD22 | 1/5/25/50/100 mg | |||||
| Clone | Cy34.1 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0012 | InVivoMAb anti-mouse CD25 (IL-2Rα) | 1/5/25/50/100 mg | |||||
| Clone | PC-61.5.3 | Isotype | Rat IgG1, λ | ||||
| Application | in vivo regulatory T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0014 | InVivoMAb anti-human CD25 (IL-2Rα) | 1/5/25/50/100 mg | |||||
| Clone | 7G7B6 | Isotype | Mouse IgG2a | ||||
| Application | in vivo regulatory T cell depletion in humanized mice, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0015-1 | InVivoMAb anti-mouse CD28 | 1/5/25/50/100 mg | |||||
| Clone | 37.51 | Isotype | Syrian Hamster IgG2 | ||||
| Application | in vitro T cell stimulation/activation, in vivo CD28 blockade | ||||||
| Recommended | Isotype Control: BE0087 Dilution Buffer: IPT060 | ||||||
| BE0015-5 | InVivoMAb anti-mouse CD28 | 1/5/25/50/100 mg | |||||
| Clone | PV-1 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vitro T cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0016-2 | InVivoMAb anti-mouse CD40 | 1/5/25/50/100 mg | |||||
| Clone | FGK4.5/FGK45 | Isotype | Rat IgG2a | ||||
| Application | in vivo CD40 activation, in vitro B cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0017-1 | InVivoMAb anti-mouse CD40L (CD154) | 1/5/25/50/100 mg | |||||
| Clone | MR-1 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blot | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0019-1 | InVivoMAb anti-human CD47 | 1/5/25/50/100 mg | |||||
| Clone | B6.H12 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0019 | InVivoMAb anti-mouse CD45RB | 1/5/25/50/100 mg | |||||
| Clone | MB23G2 (HB220) | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo anti-CD45RB_mediated tolerance induction, in vivo pre-mNK cell depletion | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0020-1 | InVivoMAb anti-mouse CD54 (ICAM-1) | 1/5/25/50/100 mg | |||||
| Clone | YN1/1.7.4 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo ICAM-1 neutralization, Immunohistochemistry (frozen), ELISA | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0020-2 | InVivoMAb anti-human CD54 (ICAM-1) | 1/5/25/50/100 mg | |||||
| Clone | R6-5-D6 | Isotype | Mouse IgG2a | ||||
| Application | in vitro T cell stimulation/activation, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0021 | InVivoMAb anti-mouse L-Selectin (CD62L) | 1/5/25/50/100 mg | |||||
| Clone | Mel-14 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD62L neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0022 | InVivoMAb anti-mouse CD70 | 1/5/25/50/100 mg | |||||
| Clone | FR70 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD70 blockade, in vitro CD70 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0023 | InVivoMAb anti-human CD71 | 1/5/25/50/100 mg | |||||
| Clone | OKT-9 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0024 | InVivoMAb anti-mouse CD80 (B7-1) | 1/5/25/50/100 mg | |||||
| Clone | 16-10A1 | Isotype | Armenian Hamster IgG2 | ||||
| Application | in vivo CD80 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0080 | ||||||
| BE0025 | InVivoMAb anti-mouse CD86 (B7-2) | 1/5/25/50/100 mg | |||||
| Clone | GL-1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD86 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0026 | InVivoMAb anti-mouse CD103 | 1/5/25/50/100 mg | |||||
| Clone | M290 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD103 neutralization, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0027 | InVivoMAb anti-mouse CD106 (VCAM-1) | 1/5/25/50/100 mg | |||||
| Clone | M/K-2.7 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo VCAM-1 neutralization, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0028 | InVivoMAb anti-mouse ICOSL (CD275) | 1/5/25/50/100 mg | |||||
| Clone | HK5.3 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo ICOSL neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0029 | InVivoMAb anti-mouse IFNγR (CD119) | 1/5/25/50/100 mg | |||||
| Clone | GR-20 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IFNγR neutralization, in vitro IFNγR neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0031 | InVivoMAb anti-mouse OX40 (CD134) | 1/5/25/50/100 mg | |||||
| Clone | OX-86 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo OX40 activation, in vitro OX40 activation, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0032 | InVivoMAb anti-mouse CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | UC10-4F10-11 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0065 | ||||||
| BE0033-1 | InVivoMAb anti-mouse OX40L (CD134L) | 1/5/25/50/100 mg | |||||
| Clone | RM134L | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of OX40/OX40L signaling, in vitro OX40L neutralization | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0033-2 | InVivoMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | J43 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0065 | ||||||
| BE0034 | InVivoMAb anti-mouse LPAM-1 (Integrin α4β7) | 1/5/25/50/100 mg | |||||
| Clone | DATK32 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo Integrin α4β7 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0035 | InVivoMAb anti-mouse MAdCAM-1 | 1/5/25/50/100 mg | |||||
| Clone | MECA-367 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo MAdCAM-1 neutralization, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0036 | InVivoMAb anti-mouse NK1.1 | 1/5/25/50/100 mg | |||||
| Clone | PK136 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo NK cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0038 | InVivoMAb anti-mouse CD11c | 1/5/25/50/100 mg | |||||
| Clone | N418 | Isotype | Armenian Hamster IgG2 | ||||
| Application | in vivo targeting of dendritic cells, Functional assays , Flow cytometry, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunofluorescence, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0039 | InVivoMAb anti-mouse/human CD44 | 1/5/25/50/100 mg | |||||
| Clone | IM7 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD44 neutralization, in vitro CD44 neutralization | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0040 | InVivoMAb anti-rat CD28 | 1/5/25/50/100 mg | |||||
| Clone | JJ319 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro T cell stimulation/activation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0042 | InVivoMAb anti-mouse IL-2 | 1/5/25/50/100 mg | |||||
| Clone | JES6-5H4 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo IL-2 neutralization, in vitro IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0043-1 | InVivoMAb anti-mouse IL-2 | 1/5/25/50/100 mg | |||||
| Clone | S4B6-1 | Isotype | Rat IgG2a | ||||
| Application | in vivo IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2) | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0080 | ||||||
| BE0043 | InVivoMAb anti-mouse IL-2 | 1/5/25/50/100 mg | |||||
| Clone | JES6-1A12 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2) | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0045 | InVivoMAb anti-mouse IL-4 | 1/5/25/50/100 mg | |||||
| Clone | 11B11 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0046 | InVivoMAb anti-mouse IL-6 | 1/5/25/50/100 mg | |||||
| Clone | MP5-20F3 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-6 neutralization, in vitro IL-6 neutralization | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0047 | InVivoMAb anti-mouse IL-6R | 1/5/25/50/100 mg | |||||
| Clone | 15A7 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of IL-6/IL-6R signaling, in vitro blocking of IL-6R signaling | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0048 | InVivoMAb anti-mouse/human IL-7 | 1/5/25/50/100 mg | |||||
| Clone | M25 | Isotype | Mouse IgG2b | ||||
| Application | in vivo IL-7 neutralization, in vivo IL-7 receptor stimulation (as a complex with IL-7) | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0049 | InVivoMAb anti-mouse IL-10 | 1/5/25/50/100 mg | |||||
| Clone | JES5-2A5 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-10 neutralization, in vitro IL-10 neutralization | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0050 | InVivoMAb anti-mouse IL-10R (CD210) | 1/5/25/50/100 mg | |||||
| Clone | 1B1.3A | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western Blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IPT065 | ||||||
| BE0051 | InVivoMAb anti-mouse IL-12 p40 | 1/5/25/50/100 mg | |||||
| Clone | C17.8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0052 | InVivoMAb anti-mouse IL-12 | 1/5/25/50/100 mg | |||||
| Clone | R1-5D9 | Isotype | Rat IgG2a | ||||
| Application | in vivo IL-12 neutralization, in vitro IL-12 neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0054 | InVivoMAb anti-mouse IFNγ | 1/5/25/50/100 mg | |||||
| Clone | R4-6A2 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IFNγ neutralization, in vitro IFNγ neutralization | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0080 | ||||||
| BE0055 | InVivoMAb anti-mouse IFNγ | 1/5/25/50/100 mg | |||||
| Clone | XMG1.2 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IFNγ neutralization, in vitro IFNγ neutralization, ELISPOT, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IPT080 | ||||||
| BE0057 | InVivoMAb anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β | 1/5/25/50/100 mg | |||||
| Clone | 1D11.16.8 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0058 | InVivoMAb anti-mouse TNFα | 1/5/25/50/100 mg | |||||
| Clone | XT3.11 | Isotype | Rat IgG1 | ||||
| Application | in vivo TNFα neutralization, in vitro TNFα neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0080 | ||||||
| BE0059 | InVivoMAb anti-mouse ICOS | 1/5/25/50/100 mg | |||||
| Clone | 7E.17G9 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of ICOS/ICOSL signaling, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0080 | ||||||
| BE0060 | InVivoMAb anti-mouse VEGFR-2 | 1/5/25/50/100 mg | |||||
| Clone | DC101 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0061 | InVivoMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | 2.43 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0062 | InVivoMAb anti-mouse/human Integrin β7 | 1/5/25/50/100 mg | |||||
| Clone | FIB504 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of integrin β7, Immunoprecipitation, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0063 | InVivoMAb anti-mouse GITR | 1/5/25/50/100 mg | |||||
| Clone | DTA-1 | Isotype | Rat IgG2b, λ | ||||
| Application | in vivo GITR stimulation | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0065 | InVivoMAb anti-mouse IL-7Rα (CD127) | 1/5/25/50/100 mg | |||||
| Clone | A7R34 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of IL-7Rα signaling, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0066 | InVivoMAb anti-mouse Thy1.2 (CD90.2) | 1/5/25/50/100 mg | |||||
| Clone | 30H12 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo ILC depletion, in vivo T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0067 | InVivoMAb anti-mouse B220 | 1/5/25/50/100 mg | |||||
| Clone | RA3.3A1/6.1 (TIB-146) | Isotype | Rat IgM | ||||
| Application | in vivo B cell depletion, in vitro B cell negative selection | ||||||
| Recommended | Isotype Control: BE0094 Dilution Buffer: IP0070 | ||||||
| BE0068 | InVivoMAb anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) | 1/5/25/50/100 mg | |||||
| Clone | 10-3.6.2 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vitro MHC class II I-A blocking, in vitro MHC class II I-A expressing cell negative selection | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0069 | InVivoMAb anti-mouse 2C TCR | 1/5/25/50/100 mg | |||||
| Clone | 1B2 | Isotype | Mouse IgG1 | ||||
| Application | Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0070 | InVivoMAb anti-mouse TCR γ/δ | 1/5/25/50/100 mg | |||||
| Clone | UC7-13D5 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo TCR γ/δ neutralization, in vitro γ/δ T cell stimulation, in vitro γ/δ T cell purification, Functional assays, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IPT060 | ||||||
| BE0071 | InVivoMAb anti-mouse/human VLA-4 (CD49d) | 1/5/25/50/100 mg | |||||
| Clone | PS/2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo VLA-4 neutralization, in vitro VLA-4 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0065 | ||||||
| BE0072 | InVivoMAb anti-mouse T15 VH and T15 VL regions of IgM | 1/5/25/50/100 mg | |||||
| Clone | AB1-2 (HB33) | Isotype | Mouse IgG1, κ | ||||
| Application | ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0075-1 | InVivoMAb anti-mouse Ly6G | 1/5/25/50/100 mg | |||||
| Clone | 1A8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0075 | InVivoMAb anti-mouse Ly6G/Ly6C (Gr-1) | 1/5/25/50/100 mg | |||||
| Clone | RB6-8C5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0076 | InVivoMAb anti-mouse Thy1 (CD90) | 1/5/25/50/100 mg | |||||
| Clone | M5/49.4.1 | Isotype | Rat IgG2a | ||||
| Application | in vitro T cell depletion | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0077 | InVivoMAb anti-mouse MHC Class I (H-2) | 1/5/25/50/100 mg | |||||
| Clone | M1/42.3.9.8 | Isotype | Rat IgG2a, κ | ||||
| Application | ex vivo blocking of MHC I-dependent interactions, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0079 | InVivoMAb anti-human MHC Class I (HLA-A, HLA-B, HLA-C) | 1/5/25/50/100 mg | |||||
| Clone | W6/32 | Isotype | Mouse IgG2a, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0065 | ||||||
| BE0083 | InVivoMAb mouse IgG1 isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0085 | InVivoMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0086 | InVivoMAb mouse IgG2b isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0087 | InVivoMAb polyclonal Syrian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0088 | InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase | 1/5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0089 | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol | 1/5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0090 | InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0091-FAB | InVivoMAb hamster IgG f(ab')2 fragments | 5/10/25/50 mg | |||||
| Clone | hamster IgG f(ab')2 Fragments | Isotype | Polyclonal | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0091 | InVivoMAb polyclonal Armenian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0092 | InVivoMAb polyclonal human IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal human IgG | Isotype | Human IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0093 | InVivoMAb polyclonal mouse IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal mouse IgG | Isotype | Mouse IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0094 | InVivoMAb polyclonal rat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rat IgG | Isotype | Rat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0095 | InVivoMAb polyclonal rabbit IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rabbit IgG | Isotype | Rabbit IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0096 | InVivoMAb recombinant human IgG1 Fc | 1/5/25/50/100 mg | |||||
| Clone | human Fc-G1 | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0097 | InVivoMAb recombinant mouse IgG2a Fc | 1/5/25/50/100 mg | |||||
| Clone | Mouse Fc-G2a | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0098 | InVivoMAb recombinant Flt-3L-Ig (hum/hum) | 1/5/25/50/100 mg | |||||
| Clone | Flt-3L-Ig (hum/hum) | Isotype | |||||
| Recommended | Isotype Control: BE0096 Dilution Buffer: IP0070 | ||||||
| BE0099 | InVivoMAb recombinant CTLA-4-Ig (hum/hum) | 1/5/25/50/100 mg | |||||
| Clone | CTLA-4-Ig (hum/hum) | Isotype | |||||
| Recommended | Isotype Control: BE0096 Dilution Buffer: IP0070 | ||||||
| BE0101 | InVivoMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™ | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo PD-L1 blockade, in vitro PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0065 | ||||||
| BE0102 | InVivoMAb anti-mouse TCRβ | 1/5/25/50/100 mg | |||||
| Clone | H57-597 (HB218) | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo T cell depletion | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0104 | InVivoMAb anti-mouse MHC Class I (H-2Kd) | 1/5/25/50/100 mg | |||||
| Clone | SF1.1.10 (HB-159) | Isotype | Mouse IgG2a, κ | ||||
| Application | Purification of MHC peptide complexes, in vivo administration, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0106 | InVivoMAb anti-LCMV nucleoprotein | 1/5/25/50/100 mg | |||||
| Clone | VL-4 | Isotype | Rat IgG2a, κ | ||||
| Application | Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0108 | InVivoMAb anti-mouse MHC Class II (I-A/I-E) | 1/5/25/50/100 mg | |||||
| Clone | M5/114 | Isotype | Rat IgG2b | ||||
| Application | in vivo MHC II blockade, Functional assays, Immunofluorescence, Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0110 | InVivoMAb anti-mouse 4-1BBL (CD137L) | 1/5/25/50/100 mg | |||||
| Clone | TKS-1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo 4-1BBL blockade, ELISA | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0111 | InVivoMAb anti-mouse NKG2D | 1/5/25/50/100 mg | |||||
| Clone | HMG2D | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo NKG2D blockade | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0112 | InVivoMAb anti-mouse PD-L2 (B7-DC) | 1/5/25/50/100 mg | |||||
| Clone | TY25 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo PD-L2 blockade, in vitro PD-L2 blockade, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0113 | InVivoMAb anti-mouse TIM-1 (CD365) | 1/5/25/50/100 mg | |||||
| Clone | RMT1-10 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TIM-1 blockade | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0114 | InVivoMAb anti-mouse TIM-2 | 1/5/25/50/100 mg | |||||
| Clone | RMT2-29 | Isotype | Rat Ig2a, λ | ||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0115 | InVivoMAb anti-mouse TIM-3 (CD366) | 1/5/25/50/100 mg | |||||
| Clone | RMT3-23 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0117 | InVivoMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | YTS 169.4 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0118 | InVivoMAb anti-mouse CD8 (Lyt 2.1) | 1/5/25/50/100 mg | |||||
| Clone | 116-13.1 (HB-129) | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0119 | InVivoMAb anti-mouse CD4 | 1/5/25/50/100 mg | |||||
| Clone | YTS 191 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0120 | InVivoMAb anti-swine MHC Class I (SLAd) | 1/5/25/50/100 mg | |||||
| Clone | 74-11-10 (HB139) | Isotype | Mouse IgG2b, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0121 | InVivoMAb anti-mouse MHC Class I (H-2Kb) | 1/5/25/50/100 mg | |||||
| Clone | AF6-88.5.5.3 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo administration, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0122 | InVivoMAb anti-rat Kappa Immunoglobulin Light Chain | 1/5/25/50/100 mg | |||||
| Clone | MAR 18.5 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-CD22 (clone Cy34.1) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0123 | InVivoMAb anti-human/rat/fish AChR | 1/5/25/50/100 mg | |||||
| Clone | Mab35 (TIB-175) | Isotype | Rat IgG1 | ||||
| Application | EAMG induction in rats, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0124 | InVivoMAb anti-mouse CD276 (B7-H3) | 1/5/25/50/100 mg | |||||
| Clone | MJ18 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo B7-H3 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0125 | InVivoMAb anti-mouse Jagged 2 | 1/5/25/50/100 mg | |||||
| Clone | HMJ2-1 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo Jagged 2 neutralization | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0127 | InVivoMAb anti-mouse Delta-like protein 4 (DLL4) | 1/5/25/50/100 mg | |||||
| Clone | HMD4-2 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo DLL4 neutralization, in vitro DLL4 neutralization | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0129 | InVivoMAb anti-mouse Notch4 | 1/5/25/50/100 mg | |||||
| Clone | HMN4-14 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo Notch4 blocking, in vitro Notch4 stimulation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0130 | InVivoMAb polyclonal goat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal goat IgG | Isotype | Goat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0131 | InVivoMAb anti-mouse CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | 9H10 | Isotype | Syrian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0087 Dilution Buffer: IP0070 | ||||||
| BE0132 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | 6A6 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo BTLA stimulation, in vivo BTLA blockade | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0134 | InVivoMAb anti-mouse CD80 (B7-1) | 1/5/25/50/100 mg | |||||
| Clone | 1G10 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD80 blockade, Affinity chromatography | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0136 | InVivoMAb anti-human E-Selectin | 1/5/25/50/100 mg | |||||
| Clone | CL2 | Isotype | Mouse IgG2a, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0139 | InVivoMAb anti-mouse/human/rat v-H-Ras | 1/5/25/50/100 mg | |||||
| Clone | Y13-238 | Isotype | Rat IgG2a | ||||
| Application | Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0140 | InVivoMAb anti-mouse MHC Class II (βchain) | 1/5/25/50/100 mg | |||||
| Clone | KL277 | Isotype | Hamster/Mouse IgG | ||||
| Application | Western blot | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0143 | InVivoMAb anti-rat β-2-Microglobulin | 1/5/25/50/100 mg | |||||
| Clone | 4C9 | Isotype | Mouse IgG1 | ||||
| Application | in vitro β2M blockade | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0144 | InVivoMAb anti-rat FcRn heavy chain heterodimers | 1/5/25/50/100 mg | |||||
| Clone | 2G3 | Isotype | Mouse IgG1 | ||||
| Application | ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0146 | InVivoMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0147 | InVivoMAb anti-mouse CD48 | 1/5/25/50/100 mg | |||||
| Clone | HM48-1 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CD48 blockade, in vitro CD48 blocking | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0150 | InVivoMAb anti-mouse CD19 | 1/5/25/50/100 mg | |||||
| Clone | 1D3 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0151 | InVivoMAb anti-mouse/human TYRP1/TRP1 (gp75) | 1/5/25/50/100 mg | |||||
| Clone | TA99 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo triggering of FcγRs, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0152 | InVivoMAb anti-mouse MHC Class I (H-2Kk) | 1/5/25/50/100 mg | |||||
| Clone | AF3-12.1.3 | Isotype | Mouse IgG1 | ||||
| Application | in vivo administration | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0153 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | PK18.6 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo stimulation of BTLA, in vitro stimulation of BTLA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0154 | InVivoMAb anti-HIV gp120 | 1/5/25/50/100 mg | |||||
| Clone | 55-36 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0155 | InVivoMAb anti-mouse Delta-like protein 1 (DLL1) | 1/5/25/50/100 mg | |||||
| Clone | HMD1-5 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo DLL1 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0158 | InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) | 1/5/25/50/100 mg | |||||
| Clone | 15-3-1S (HB-13) | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo administration, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0159 | InVivoMAb anti-Influenza A virus NP | 1/5/25/50/100 mg | |||||
| Clone | H16-L10-4R5 (HB-65) | Isotype | Mouse IgG2a | ||||
| Application | Immunoprecipitation, Immunohistochemistry (paraffin), in vivo induction of passive immunity to influenza A virus, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0161 | InVivoMAb anti-mouse DR5 (CD262) | 1/5/25/50/100 mg | |||||
| Clone | MD5-1 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo induction TRAIL-mediated apoptosis, in vitro induction TRAIL-mediated apoptosis | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0162 | InVivoMAb anti-human Glycophorin A (type M) | 1/5/25/50/100 mg | |||||
| Clone | 6A7M | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro GPA blockade | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0164 | InVivoMAb anti-mouse CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | 9D9 | Isotype | Mouse IgG2b | ||||
| Application | in vivo CTLA-4 neutralization, Western blot, in vivo intra-tumoral regulatory T cell depletion | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0165 | InVivoMAb anti-mouse Nonclassical MHC Class I molecule Qa-1b | 1/5/25/50/100 mg | |||||
| Clone | 4C2.4A7.5H11 | Isotype | Mouse IgG1 | ||||
| Application | Western blot, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0166 | InVivoMAb anti-mouse Vβ4 TCR | 1/5/25/50/100 mg | |||||
| Clone | KT4 | Isotype | Rat IgG2b | ||||
| Application | in vivo administration, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0167 | InVivoMAb anti-mouse/rat MHC Class II (I-Ek/RT1-D) | 1/5/25/50/100 mg | |||||
| Clone | 14-4-4S (HB-32) | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of antigen presentation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0168 | InVivoMAb anti-mouse Vγ2 TCR | 1/5/25/50/100 mg | |||||
| Clone | UC3-10A6 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo γδ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0169 | InVivoMAb anti-mouse 4-1BB (CD137) | 1/5/25/50/100 mg | |||||
| Clone | LOB12.3 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo activation of 4-1BB | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0080 | ||||||
| BE0171 | InVivoMAb anti-mouse TIM-4 | 1/5/25/50/100 mg | |||||
| Clone | RMT4-53 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo TIM-4 blockade, in vitro TIM-4 blockade, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0172 | InVivoMAb anti-mouse MHC Class I (H-2Kb) | 1/5/25/50/100 mg | |||||
| Clone | Y-3 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo MHC II blockade, Functional assays, Purification of MHC peptide complexes, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0173 | InVivoMAb anti-mouse/rat IL-17A | 1/5/25/50/100 mg | |||||
| Clone | 17F3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-17A neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0174 | InVivoMAb anti-mouse LAG-3 | 1/5/25/50/100 mg | |||||
| Clone | C9B7W | Isotype | Rat IgG1, κ | ||||
| Application | in vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0175 | InVivoMAb anti-mouse CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | R17 217.1.3/TIB-219 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo depletion of CD71+ cells | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0176 | InVivoMAb anti-mouse Kappa Immunoglobulin Light Chain | 1/5/25/50/100 mg | |||||
| Clone | 187.1 (HB-58) | Isotype | Rat IgG1, κ | ||||
| Application | Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0178 | InVivoMAb anti-mouse MHC class II (I-A) | 1/5/25/50/100 mg | |||||
| Clone | Y-3P | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blockade of TCR stimulation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0179 | InVivoMAb anti-mouse CD1d (CD1.1) | 1/5/25/50/100 mg | |||||
| Clone | 20H2 (HB323) | Isotype | Rat IgG1, κ | ||||
| Application | iNKT cell neutralization, in vivo CD1d blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0180 | InVivoMAb anti-mouse MHC Class I (H-2Kd, H-2Dd) | 1/5/25/50/100 mg | |||||
| Clone | 34-1-2S | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo activation of APCs | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0181 | InVivoMAb anti-mouse IL-9 | 1/5/25/50/100 mg | |||||
| Clone | 9C1 | Isotype | Mouse IgG2a | ||||
| Application | in vivo IL-9 neutralization | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0182 | InVivoMAb anti-mouse Vβ8 TCR | 1/5/25/50/100 mg | |||||
| Clone | F23.1 | Isotype | Mouse IgG2a, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0183 | InVivoMAb anti-mouse Ter-119 | 1/5/25/50/100 mg | |||||
| Clone | TER-119 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo administration, in vitro erythrocyte negative selection, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0185 | InVivoMAb anti-mouse/human/rat CCL2 (MCP-1) | 1/5/25/50/100 mg | |||||
| Clone | 2H5 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo CCL2 neutralization, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0186 | InVivoMAb anti-mouse PSGL-1 (CD162) | 1/5/25/50/100 mg | |||||
| Clone | 4RA10 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo PSGL-1 blockade, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0187 | InVivoMAb anti-rat CD80 (B7-1) | 1/5/25/50/100 mg | |||||
| Clone | 3H5 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CD80 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0188 | InVivoMAb anti-human PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | J116 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0189 | InVivoMAb anti-human CD40 | 1/5/25/50/100 mg | |||||
| Clone | G28.5 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CD40 stimulation, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0190 | InVivoMAb anti-human CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | BN13 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vitro CTLA-4 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0191 | InVivoMAb anti-mouse RANKL (CD254) | 1/5/25/50/100 mg | |||||
| Clone | IK22/5 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo RANKL blockade | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0065 | ||||||
| BE0192 | InVivoMAb anti-human CD11a (LFA-1α) | 1/5/25/50/100 mg | |||||
| Clone | R7-1 | Isotype | Mouse IgG1 | ||||
| Application | Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0193 | InVivoMAb anti-human PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | J110 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-1 blockade in humanized mice, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0194 | InVivoMAb anti-Phosphotyrosine | 1/5/25/50/100 mg | |||||
| Clone | 4G10 | Isotype | Mouse IgG2b | ||||
| Application | ELISA, Western blot | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0196 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | PJ196 | Isotype | Mouse IgG1 | ||||
| Application | in vivo BTLA blockade, in vitro T cell stimulation/activation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0198 | InVivoMAb anti-mouse/human IL-5 | 1/5/25/50/100 mg | |||||
| Clone | TRFK5 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-5 neutralization, in vivo eosinophil depletion | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0199 | InVivoMAb anti-mouse IL-4 | 1/5/25/50/100 mg | |||||
| Clone | BVD6-24G2 | Isotype | Rat IgG1, κ | ||||
| Application | ELISA, ELISPOT, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0200 | InVivoMAb anti-mouse Pan-endothelial Cell Antigen (MECA-32) | 1/5/25/50/100 mg | |||||
| Clone | MECA-32 | Isotype | Rat IgG2a, κ | ||||
| Application | Immunohistochemistry (frozen), Flow cytometry, Western blot, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0201 | InVivoMAb anti-mouse/human KLRG-1 | 1/5/25/50/100 mg | |||||
| Clone | 2F1 | Isotype | Syrian Hamster IgG | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0087 Dilution Buffer: IP0070 | ||||||
| BE0202 | InVivoMAb anti-mouse Siglec-H | 1/5/25/50/100 mg | |||||
| Clone | 440c | Isotype | Rat IgG2b | ||||
| Application | in vivo administration, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0203 | InVivoMAb anti-mouse Ly6C | 1/5/25/50/100 mg | |||||
| Clone | Monts 1 | Isotype | Rat IgG2a | ||||
| Application | in vivo macrophage depletion (in combination with clodronate liposomes), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0204 | InVivoMAb anti-mouse CSF1 | 1/5/25/50/100 mg | |||||
| Clone | 5A1 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo CSF1 neutralization | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0080 | ||||||
| BE0206 | InVivoMAb anti-mouse F4/80 | 1/5/25/50/100 mg | |||||
| Clone | CI:A3-1 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo Monocyte/Macrophage depletion, Functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0207 | InVivoMAb anti-mouse MHC Class I (H-2Kb) bound to SIINFEKL peptide (OVA residues 257-264) | 1/5/25/50/100 mg | |||||
| Clone | 25-D1.16 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of Kb -SIINFEKL, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0209 | InVivoMAb anti-mouse CD73 | 1/5/25/50/100 mg | |||||
| Clone | TY/23 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD73 blockade, in vitro CD73 blockade | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0210 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | 8F4 | Isotype | Mouse IgG1, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0211 | InVivoMAb anti-human CD1a | 1/5/25/50/100 mg | |||||
| Clone | OKT-6 | Isotype | Mouse IgG1 | ||||
| Application | in vitro CD1a blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0213 | InVivoMAb anti-mouse CSF1R (CD115) | 1/5/25/50/100 mg | |||||
| Clone | AFS98 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0214 | InVivoMAb anti-mouse Thy1.1 (CD90.1) | 1/5/25/50/100 mg | |||||
| Clone | 19E12 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo T cell depletion | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0216 | InVivoMAb anti-human YB-1 | 1/5/25/50/100 mg | |||||
| Clone | 21A3 | Isotype | Mouse IgG1 | ||||
| Application | Immunohistochemistry (paraffin), Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0218 | InVivoMAb anti-mouse Galectin-9 | 1/5/25/50/100 mg | |||||
| Clone | RG9-1 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo Galectin-9 blockade in vitro Galectin-9 blockade | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0220 | InVivoMAb anti-mouse CD209b (SIGN-R1) | 1/5/25/50/100 mg | |||||
| Clone | 22D1 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo SIGN-R1 blockade, Immunohistochemistry (frozen), Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0222 | InVivoMAb anti-rat FcRn heavy chain heterodimers | 1/5/25/50/100 mg | |||||
| Clone | 1G3 | Isotype | Mouse IgG1 | ||||
| Application | Immunofluorescence, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0223 | InVivoMAb anti-mouse CD8β (Lyt 3.2) | 1/5/25/50/100 mg | |||||
| Clone | 53-5.8 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo CD8+ T cell depletion, in vitro CD8 blockade, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0224 | InVivoMAb anti-human CD32 (FcγRIIA) | 1/5/25/50/100 mg | |||||
| Clone | IV.3 | Isotype | Mouse IgG2b | ||||
| Application | in vivo FcγRIIA blockade in humanized mice, in vitro FcγRIIA blockade, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0225 | InVivoMAb anti-mouse TIM-4 | 1/5/25/50/100 mg | |||||
| Clone | RMT4-54 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro TIM-4 blocking, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0228 | InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) | 1/5/25/50/100 mg | |||||
| Clone | 16-1-2N (HB14) | Isotype | Mouse IgG2a | ||||
| Application | Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0231 | InVivoMAb anti-human CD3 | 1/5/25/50/100 mg | |||||
| Clone | UCHT1 (Leu-4) (T3) | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0232 | InVivoMAb anti-mouse CD29 | 1/5/25/50/100 mg | |||||
| Clone | KMI6 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD29 neutralization, in vitro CD29 neutralization, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0233 | InVivoMAb anti-mouse IL-12 p75 | 1/5/25/50/100 mg | |||||
| Clone | R2-9A5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo IL-12p75 neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0080 | ||||||
| BE0234 | InVivoMAb anti-human IL-12 p70 | 1/5/25/50/100 mg | |||||
| Clone | 20C2 | Isotype | Rat IgG1, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0235 | InVivoMAb anti-human IFNγ | 1/5/25/50/100 mg | |||||
| Clone | B133.5 | Isotype | Mouse IgG1 | ||||
| Application | in vivo IFNγ neutralization in humanized mice, in vitro IFNγ neutralization | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0236 | InVivoMAb anti-mouse Podoplanin (gp38) | 1/5/25/50/100 mg | |||||
| Clone | 8.1.1 | Isotype | Syrian Hamster IgG | ||||
| Application | in vivo PDPN blockade, in vitro PDPN blockade, Immunofluorescence, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0087 Dilution Buffer: IP0070 | ||||||
| BE0237 | InVivoMAb anti-mouse IL-18 | 1/5/25/50/100 mg | |||||
| Clone | YIGIF74-1G7 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-18 neutralization, in vitro IL-18 neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0238 | InVivoMAb anti-human c-myc | 1/5/25/50/100 mg | |||||
| Clone | 9E10 | Isotype | Mouse IgG1 | ||||
| Application | Western blot, ELISA, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0239 | InVivoMAb anti-mouse 4-1BB (CD137) | 1/5/25/50/100 mg | |||||
| Clone | 3H3 | Isotype | Rat IgG2a | ||||
| Application | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0240 | InVivoMAb anti-human IL-4 | 1/5/25/50/100 mg | |||||
| Clone | MP4-25D2 | Isotype | Rat IgG1, κ | ||||
| Application | in vitro IL-4 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0241 | InVivoMAb anti-mouse IFNAR-1 | 1/5/25/50/100 mg | |||||
| Clone | MAR1-5A3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0243 | InVivoMAb anti-mouse IL-1α | 1/5/25/50/100 mg | |||||
| Clone | ALF-161 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo IL-1α neutralization, in vitro IL-1α neutralization | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0244 | InVivoMAb anti-mouse/rat/rabbit TNFα | 1/5/25/50/100 mg | |||||
| Clone | TN3-19.12 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo TNFα neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0245 | InVivoMAb anti-human IFNγ | 1/5/25/50/100 mg | |||||
| Clone | B27 | Isotype | Mouse IgG1 | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0246 | InVivoMAb anti-mouse/rat IL-1β | 1/5/25/50/100 mg | |||||
| Clone | B122 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo IL-1β neutralization, in vitro IL-1β neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0247 | InVivoMAb anti-mouse TNFR2 (CD120b) | 1/5/25/50/100 mg | |||||
| Clone | TR75-54.7 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo TNFR2 blockade, in vitro TNFR2 blockade | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0248 | InVivoMAb anti-human CD28 | 1/5/25/50/100 mg | |||||
| Clone | 9.3 | Isotype | Mouse IgG2a | ||||
| Application | in vitro T cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0249 | InVivoMAb anti-mouse CXCR3 (CD183) | 1/5/25/50/100 mg | |||||
| Clone | CXCR3-173 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CXCR3 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0250 | InVivoMAb anti-rat IgG1 | 1/5/25/50/100 mg | |||||
| Clone | RG11/39.4 | Isotype | Mouse IgG2c, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0251 | InVivoMAb anti-rat IgG2a | 1/5/25/50/100 mg | |||||
| Clone | RG7/1.30 | Isotype | Mouse IgG2b, κ | ||||
| Application | Immunofluorescence, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0252 | InVivoMAb anti-rat IgG2b | 1/5/25/50/100 mg | |||||
| Clone | RG7/11.1 | Isotype | Mouse IgG2b, κ | ||||
| Application | ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0256 | InVivoMAb anti-mouse IL-1 R (CD121a) | 1/5/25/50/100 mg | |||||
| Clone | JAMA-147 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo IL-1 R blockade, in vitro IL-1 R blockade | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IPT060 | ||||||
| BE0257 | InVivoMAb anti-mouse TCR Vγ1.1/Cr4 | 1/5/25/50/100 mg | |||||
| Clone | 2.11 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo Vγ1 TCR+ cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0258 | InVivoMAb anti-mouse IL-21R | 1/5/25/50/100 mg | |||||
| Clone | 4A9 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-21R blockade | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0259 | InVivoMAb anti-mouse GM-CSF | 1/5/25/50/100 mg | |||||
| Clone | MP1-22E9 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo GM-CSF neutralization, in vitro GM-CSF neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0260 | InVivoMAb Armenian hamster IgG isotype control, anti-glutathione S-transferase | 1/5/25/50/100 mg | |||||
| Clone | PIP | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0261 | InVivoMAb anti-mouse CD3ε | 1/5/25/50/100 mg | |||||
| Clone | KT3 | Isotype | Rat IgG2a | ||||
| Application | in vitro T cell negative selection, in vitro T cell stimulation/activation, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0262 | InVivoMAb anti-human CD44 | 1/5/25/50/100 mg | |||||
| Clone | Hermes-1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD44 blockade in xenografts, in vitro CD44 blockade, Western blot, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0270 | InVivoMAb anti-mouse CD47 (IAP) | 1/5/25/50/100 mg | |||||
| Clone | MIAP301 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD47 blockade, in vitro CD47 blockade, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0271 | InVivoMAb anti-mouse CD132 (common γ chain) | 1/5/25/50/100 mg | |||||
| Clone | 3E12 | Isotype | Rat IgG2b | ||||
| Application | in vivo γc blockade, Functional assays, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0272 | InVivoMAb anti-mouse CD122 (IL-2Rβ) | 1/5/25/50/100 mg | |||||
| Clone | 5H4 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro NK cell negative selection, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0273 | InVivoMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™ | Isotype | Rat IgG2a | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0274 | InVivoMAb anti-mouse TIGIT | 1/5/25/50/100 mg | |||||
| Clone | 1G9 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TIGIT stimulation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0275 | InVivoMAb anti-mouse TIM-3 (CD366) | 1/5/25/50/100 mg | |||||
| Clone | B8.2C12 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0276 | InVivoMAb anti-human/monkey CD20 | 1/5/25/50/100 mg | |||||
| Clone | 2H7 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo B cell depletion in hCD20 Tg mice, Immunohistochemistry (frozen), Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0277 | InVivoMAb anti-human/rat HER2 (neu) | 1/5/25/50/100 mg | |||||
| Clone | 7.16.4 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo HER2/neu inhibition, in vitro HER2/neu inhibition, Immunoprecipitation, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0278 | InVivoMAb anti-human EGFR | 1/5/25/50/100 mg | |||||
| Clone | 225 (HB-8508) | Isotype | Mouse IgG1 | ||||
| Application | in vitro EGFR blockade, in vivo EGFR blockade in xenografts, Western blot, Functional assays | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0279 | InVivoMAb anti-human EGFR | 1/5/25/50/100 mg | |||||
| Clone | 528 | Isotype | Mouse IgG2a | ||||
| Application | in vitro EGFR blockade, in vivo EGFR blockade in xenografts, Western blot, Functional assays, Immunoprecipitation, Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0280 | InVivoMAb anti-mouse c-Kit (CD117) | 1/5/25/50/100 mg | |||||
| Clone | 2B8 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, Immunofluorescence, Immunohistochemistry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0281 | InVivoMAb anti-human CD19 | 1/5/25/50/100 mg | |||||
| Clone | 4G7 | Isotype | Mouse IgG1 | ||||
| Application | Flow cytometry, Functional assays, Immunofluorescence, Chimeric antigen receptor construction (see Poirot, L., et al. reference) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0282 | InVivoMab anti-mouse IL-3 | 1/5/25/50/100 mg | |||||
| Clone | MP2-8F8 | Isotype | Rat IgG1 | ||||
| Application | in vivo IL-3 neutralization, in vitro IL-3 neutralization, in vivo IL-3 receptor stimulation (as a complex with IL-3), ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0065 | ||||||
| BE0283 | InVivoMAb anti-mouse/human/rat CD47 (IAP) | 1/5/25/50/100 mg | |||||
| Clone | MIAP410 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CD47 blockade, in vitro CD47 blocking, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0285 | InVivoMAb anti-human PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 29E.2A3 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0287 | InVivoMAb anti-mouse IFNγRα (CD119) | 1/5/25/50/100 mg | |||||
| Clone | 2E2 | Isotype | Armenian Hamster IgG | ||||
| Application | Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0288 | InVivoMAb anti-human CD4 | 1/5/25/50/100 mg | |||||
| Clone | RPA-T4 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0289 | InVivoMAb anti-mouse TIM-1 (CD365) | 1/5/25/50/100 mg | |||||
| Clone | 3B3 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TIM-1 activation, in vitro T cell stimulation/activation, Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0290 | InVivoMAb rat IgG1 Isotype control, anti-trinitrophenol | 1/5/25/50/100 mg | |||||
| Clone | TNP6A7 | Isotype | Rat IgG1, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0291 | InVivoMAb anti-human/monkey CD28 | 1/5/25/50/100 mg | |||||
| Clone | CD28.2 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro T cell stimulation/activation, Immunoprecipitation, Flow cytometry, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0292 | InVivoMAb anti-human/monkey CD40L (CD154) | 1/5/25/50/100 mg | |||||
| Clone | 5C8 | Isotype | Mouse IgG2a | ||||
| Application | in vitro blocking of CD40/CD40L signaling, in vivo blocking of CD40/CD40L signaling, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0293 | InVivoMAb anti-mouse c-Kit (CD117) | 1/5/25/50/100 mg | |||||
| Clone | ACK2 | Isotype | Rat IgG2b | ||||
| Application | in vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0294 | InVivoMAb anti-mouse E-selectin (CD62E) | 1/5/25/50/100 mg | |||||
| Clone | 9A9 | Isotype | Rat IgG2b | ||||
| Application | in vivo E-selectin blockade, in vitro E-selectin blockade, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0296 | InVivoMAb anti-mouse 4-1BB (CD137) | 1/5/25/50/100 mg | |||||
| Clone | 17B5 | Isotype | Syrian Hamster IgG | ||||
| Application | in vitro 4-1BB blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0087 Dilution Buffer: IP0070 | ||||||
| BE0297 | InVivoMAb human IgG1 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0298 | InVivoMAb anti-mouse CD122 (IL-2Rβ) | 1/5/25/50/100 mg | |||||
| Clone | TM-Beta 1 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo NK cell depletion, in vivo CD122 blockade, in vitro IL-2R blockade, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0080 | ||||||
| BE0299 | InVivoMAb anti-mouse CD200 (OX2) | 1/5/25/50/100 mg | |||||
| Clone | OX-90 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD200 blockade, in vitro CD200 blockade, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0300 | InVivoMAb anti-mouse CD45.2 | 1/5/25/50/100 mg | |||||
| Clone | 104.2 | Isotype | Mouse IgG2a, κ | ||||
| Application | Flow cytometry, in vivo CD45.2 blockade, in vitro CD45.2 blockade, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0301 | InVivoMAb human IgG2 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0302 | InVivoMAb anti-mouse CD20 | 25/50/100 mg | |||||
| Clone | AISB12 | Isotype | Rat IgG2a, κ | ||||
| Application | Flow cytometry, Western blot, Not recommended for in vivo B cell depletion | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0303 | InVivoMAb anti-mouse IL-17F | 1/5/25/50/100 mg | |||||
| Clone | MM17F8F5.1A9 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-17F neutralization | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0304 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | 6F7 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo BTLA+ B cell and CD4 T cell depletion*, Flow cytometry, *see description for details | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0305 | InVivoMAb anti-mouse CLEC9A (CD370) | 1/5/25/50/100 mg | |||||
| Clone | 7H11 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo CLEC9A blockade, in vivo Ag targeting to CLEC9A+ DCs, Western blot, ELISA, Immunoprecipitation, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0306 | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | 1/5/25/50/100 mg | |||||
| Clone | L243 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vitro blocking of MHC class II HLA-DR, HLA class II binding assay, in vitro MHC class II HLA-DR expressing cell negative selection, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0307 | InVivoMAb anti-mouse CD16/CD32 | 1/5/25/50/100 mg | |||||
| Clone | 2.4G2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo Fc receptor blocking, Fc receptor blocking, flow cytometry, Fc receptor blocking, immunofluorescence | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0080 | ||||||
| BE0308 | InVivoMAb anti-rat CD4 | 1/5/25/50/100 mg | |||||
| Clone | OX-38 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0309 | InVivoMAb anti-mouse CXCL9 (MIG) | 1/5/25/50/100 mg | |||||
| Clone | MIG-2F5.5 | Isotype | Armenian Hamster IgG, κ | ||||
| Application | in vivo CXCL9 neutralization, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0310 | InVivoMAb anti-mouse VISTA | 1/5/25/50/100 mg | |||||
| Clone | 13F3 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of VISTA signaling, in vitro blocking of VISTA signaling, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0311 | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | 1/5/25/50/100 mg | |||||
| Clone | 927 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo pDC depletion, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0312 | InVivoMAb anti-mouse IFNγ | 1/5/25/50/100 mg | |||||
| Clone | H22 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo IFNγ neutralization, in vitro IFNγ neutralization | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0313 | InVivoMAb anti-mouse IL-23 (p19) | 10/25/50/100 mg | |||||
| Clone | G23-8 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-23p19 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0314 | InVivoMAb anti-mouse TIM-1 (CD365) | 1/5/25/50/100 mg | |||||
| Clone | 3D10 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo TIM-1 blockade, in vitro TIM-1 blockade | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0315 | InVivoMAb anti-mouse IL-15 | 10/25/50/100 mg | |||||
| Clone | AIO.3 | Isotype | Rat IgG2a, λ | ||||
| Application | in vivo IL-15 neutralization, in vitro IL-15 neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0316 | InVivoMAb anti-mouse CCR3 (CD193) | 1/5/25/50/100 mg | |||||
| Clone | 6S2-19-4 | Isotype | Rat IgG2b, λ | ||||
| Application | in vivo eosinophil depletion | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0317 | InVivoMAb anti-mouse CD38 | 1/5/25/50/100 mg | |||||
| Clone | NIMR5 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD38 stimulation, in vitro CD38 stimulation, in vitro B cell activation, Immunofluorescence, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0318 | InVivoMAb anti-human Ganglioside GD2 | 1/5/25/50/100 mg | |||||
| Clone | 14G2a | Isotype | Mouse IgG2a, κ | ||||
| Application | in vitro induction of apoptosis in GD2+ cells, in vivo inhibition of GD2+ tumor cell growth | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0319 | InVivoMAb anti-mouse FasL (CD178) | 1/5/25/50/100 mg | |||||
| Clone | MFL3 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo FasL blockade, In vitro FasL blockade, Functional assay, Immunohistochemistry (paraffin), Flow Cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0320 | InVivoMAb anti-mouse Ly6G/Ly6C | 1/5/25/50/100 mg | |||||
| Clone | NIMP-R14 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo neutrophil depletion, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0321 | InVivoMAb anti-mouse NKG2A/C/E | 1/5/25/50/100 mg | |||||
| Clone | 20D5 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo NKG2A blockade (see description), in vitro NKG2A blockade, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0322 | InVivoMAb anti-mouse CD172a (SIRPα) | 1/5/25/50/100 mg | |||||
| Clone | P84 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo SIRPα blocking, In vitro SIRPα blocking, Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0323 | InVivoMAb anti-mouse TL1A (TNFSF15) | 1/5/25/50/100 mg | |||||
| Clone | 5G4.6 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo TL1A neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0324 | InVivoMAb anti-human/mouse denatured collagen type-I (RGD motif) | 1/5/25/50/100 mg | |||||
| Clone | XL313 | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot, Immunofluorescence, in vivo administration (see description) | ||||||
| Recommended | Dilution Buffer: - | ||||||
| BE0325 | InVivoMAb anti-West Nile/dengue virus E protein | 1/5/25/50/100 mg | |||||
| Clone | E60 | Isotype | Mouse IgG2a, κ | ||||
| Application | Neutralization of WNV, Neutralization of DENV1,2,3,4 | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0326 | InVivoMAb anti-mouse IL-27 p28 | 1/5/25/50/100 mg | |||||
| Clone | MM27.7B1 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo IL-27 p28 neutralization, in vitro IL-27 p28 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0327 | InVivoMAb anti-human IL-9 | 1/5/25/50/100 mg | |||||
| Clone | MH9A4 | Isotype | Mouse IgG2b, κ | ||||
| Application | Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0328 | InVivoMAb anti-mouse CD28 | 1/5/25/50/100 mg | |||||
| Clone | D665 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo T cell stimulation/activation, in vitro T cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0329 | InVivoMAb anti-mouse CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | 8D3 | Isotype | Rat IgG2a | ||||
| Application | in vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0330 | InVivoMAb anti-mouse CD69 | 1/5/25/50/100 mg | |||||
| Clone | CD69.2.2 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo down-regulation of CD69 expression, Functional assays | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0331 | InVivoMAb anti-rat/mouse CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | OX-26 | Isotype | Mouse IgG2a, κ | ||||
| Application | Targeted drug delivery to the brain, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0332 | InVivoMAb anti-mouse FGL-1 | 1/5/25/50/100 mg | |||||
| Clone | 177R4 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo FGL-1 blockade, in vitro FGL-1 blockade, Flow cytometry, Immunohistochemistry (paraffin) | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0333 | InVivoMAb anti-mouse/human/rat LRP1 (CD91) | 1/5/25/50/100 mg | |||||
| Clone | 11H4 | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot, Immunofluorescence, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0334 | InVivoMAb anti-mouse NKG2D (CD314) | 1/5/25/50/100 mg | |||||
| Clone | CX5 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo NKG2D blockade, in vitro NKG2D blockade, Flow Cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0335 | InVivoMAb anti-human MAGE-C2 (CT10) | 1/5/25/50/100 mg | |||||
| Clone | LX-CT10.5 | Isotype | Mouse IgG2a, κ | ||||
| Application | Immunohistochemistry (paraffin), Immunofluorescence, Western blot | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0336 | InVivoMAb anti-human MUC1 (CD227) | 1/5/25/50/100 mg | |||||
| Clone | C595 (NCRC48) | Isotype | Mouse IgG3, κ | ||||
| Application | in vivo administration in mouse xenograft models, Immunohistochemistry (paraffin), Immunofluorescence, in vitro cell cytotoxicity assay, Western blot | ||||||
| Recommended | Isotype Control: BE0093 Dilution Buffer: IP0070 | ||||||
| BE0337 | InVivoMAb anti-mouse CD96 | 1/5/25/50/100 mg | |||||
| Clone | 3.3 | Isotype | Rat IgG1, λ | ||||
| Application | in vivo CD96 blocking, in vitro CD96 blocking, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0338 | InVivoMAb anti-human CD220 (Insulin Receptor) | 1/5/25/50/100 mg | |||||
| Clone | IR 83-22 | Isotype | Mouse IgG1 | ||||
| Application | Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0339 | InVivoMAb anti-mouse NKG2AB6 | 1/5/25/50/100 mg | |||||
| Clone | 16A11 | Isotype | Mouse IgG2b, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0340 | InVivoMAb anti-human/monkey MDR-1 (CD243) | 1/5/25/50/100 mg | |||||
| Clone | UIC2 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo MDR-1 blocking/depletion in xenogeneic murine, tumor models, in vitro MDR-1 blocking, Immunohistochemistry (paraffin) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0341 | InVivoMAb anti-human EphA2 | 1/5/25/50/100 mg | |||||
| Clone | B2D6 | Isotype | Mouse IgG2b, κ | ||||
| Application | Immunohistochemistry (paraffin), Immunoprecipitation, Functional assay | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0342 | InVivoMAb recombinant Flt-3L-Ig (hum/hum) | 1/5/25/50/100 mg | |||||
| Clone | Flt-3L Fc-G1 | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0343 | InVivoMAb anti-human CD71 (TfR) | 1/5/25/50/100 mg | |||||
| Clone | 5E9C11 | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0344 | InVivoMAb anti-mouse TIM-4 | 1/5/25/50/100 mg | |||||
| Clone | F31-5G3 | Isotype | Rat IgG1, κ | ||||
| Application | Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0345 | InVivoMAb anti-mouse/rat/bovine VLDL-R | 1/5/25/50/100 mg | |||||
| Clone | IgG-6A6 | Isotype | Mouse IgG1, λ | ||||
| Application | Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0346 | InVivoMAb anti-mouse CD326 (EpCAM) | 1/5/25/50/100 mg | |||||
| Clone | G8.8 | Isotype | Rat IgG2a, κ | ||||
| Application | Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0347 | InVivoMAb anti-human CSF1R (CD115) | 1/5/25/50/100 mg | |||||
| Clone | 2-4A5-4 | Isotype | Rat IgG1, κ | ||||
| Application | in vitro CSF1R neutralization, Immunohistochemistry (paraffin), Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0348 | InVivoMAb anti-mouse CD27 | 1/5/25/50/100 mg | |||||
| Clone | RM27-3E5 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD27 stimulation, in vitro CD27 stimulation, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0350 | InVivoMAb anti-mouse/human PrP (prion protein) | 1/5/25/50/100 mg | |||||
| Clone | TW1 | Isotype | Mouse IgG2a | ||||
| Application | in vivo PrP blocking, Western blot | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0351 | InVivoMAb anti-human NKG2D (CD314) | 1/5/25/50/100 mg | |||||
| Clone | 1D11 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro NKG2D blocking, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0352 | InVivoMAb anti-mouse E-Cadherin (CD324) | 1/5/25/50/100 mg | |||||
| Clone | DECMA-1 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo E-Cadherin neutralization, In vitro E-Cadherin neutralization, Immunofluorescence, Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0353 | InVivoMAb anti-mouse/human/rat/monkey ICOS (CD278) | 1/5/25/50/100 mg | |||||
| Clone | C398.4A | Isotype | Armenian Hamster IgG | ||||
| Application | in vitro T cell stimulation/activation, Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0354 | InVivoMAb anti-human CD2 | 1/5/25/50/100 mg | |||||
| Clone | CB.219 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo CD2 blockade in huCD2tg mice | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0355 | InVivoMAb anti-human CA19-9 | 1/5/25/50/100 mg | |||||
| Clone | 1116-NS-19-9 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0356 | InVivoMAb anti-mouse CD20 | 1/5/25/50/100 mg | |||||
| Clone | MB20-11 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo B cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0357 | InVivoMAb anti-SARS-CoV-2 S protein (RBD epitope A) | 1/5/25/50/100 mg | |||||
| Clone | SARS2-01 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0358 | InVivoMAb anti-SARS-CoV-2 S protein (NTD) | 1/5/25/50/100 mg | |||||
| Clone | SARS2-29 | Isotype | Mouse IgG1, κ | ||||
| Application | Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0359 | InVivoMAb anti-SARS-CoV-2 S protein (RBD epitope B) | 1/5/25/50/100 mg | |||||
| Clone | SARS2-34 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0360 | InVivoMAb anti-mouse CD24 | 1/5/25/50/100 mg | |||||
| Clone | M1/69 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo administration, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0361 | InVivoMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.2H11 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of PD-L1/CD80 (B7-1) interactions, in vitro blocking of PD-L1/CD80 (B7-1) interactions, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0362 | InVivoMAb anti-human CEACAM 1/3/5/6/8 | 1/5/25/50/100 mg | |||||
| Clone | 6G5j | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot, ELISA, Immunofluorescence, Immunohistochemistry (paraffin), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0363 | InVivoMAb anti-human CEACAM7 | 1/5/25/50/100 mg | |||||
| Clone | P3-7B | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot*, ELISA*, Immunoprecipitation*, Immunohistochemistry*, Flow cytometry* *Based on unpublished data |
||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0364 | InVivoMAb anti-mouse BTLA (CD272) | 1/5/25/50/100 mg | |||||
| Clone | HMBT-6B2 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo BTLA blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0365 | InVivoMAb anti-mouse CD80 (B7-1) | 1/5/25/50/100 mg | |||||
| Clone | RM80 | Isotype | Rat IgG2a | ||||
| Application | in vivo CD80 blockade, in vitro CD80 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0366 | InVivoMAb mouse IgG2c isotype control, anti-dengue virus | 1/5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0367 | InVivoMAb anti-human CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | B3/25 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CD71 targeting, in vivo CD71 targeting, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0368 | InVivoMAb anti-human/mouse/rat amyloid-beta | 1/5/25/50/100 mg | |||||
| Clone | MOAB-2 | Isotype | Mouse IgG2b, λ | ||||
| Application | Western blot, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, ELISA | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0369 | InVivoMAb polyclonal llama IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal llama IgG | Isotype | Llama IgG | ||||
| Recommended | Dilution Buffer: - | ||||||
| BE0370 | InVivoMAb anti-human CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | T56/14 | Isotype | Mouse IgG1, κ | ||||
| Application | Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0371 | InVivoMAb anti-mouse IL-12 p35 | 1/5/25/50/100 mg | |||||
| Clone | C18.2 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-12 p35 neutralization, in vitro IL-12 p35 neutralization, ELISA, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0372 | InVivoMAb anti-mouse/human osteopontin (SPP1) | 1/5/25/50/100 mg | |||||
| Clone | 100D3 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo OPN neutralization, in vitro OPN neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0373 | InVivoMAb anti-mouse osteopontin (SPP1) | 1/5/25/50/100 mg | |||||
| Clone | 103D6 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo OPN neutralization, in vitro OPN neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0374 | InVivoMAb anti-mouse FAP | 1/5/25/50/100 mg | |||||
| Clone | 73.3 | Isotype | Mouse IgG1, κ | ||||
| Application | Chimeric antigen receptor construction, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0375 | InVivoMAb anti-human EGFR | 1/5/25/50/100 mg | |||||
| Clone | 425 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo EGFR blockade in xenografts, in vitro EGFR blockade, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0376 | InVivoMAb anti-human CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | 2C1 | Isotype | Mouse IgG2b, κ | ||||
| Application | Flow cytometry*, Immunoprecipitation*, Western blot* *Based on unpublished data |
||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0377 | InVivoMAb anti-mouse CD31 (PECAM-1) | 1/5/25/50/100 mg | |||||
| Clone | 390 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD31 blocking, Intravital imaging, Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0378 | InVivoMAb anti-mouse CD16.2 (FcγRIV) | 1/5/25/50/100 mg | |||||
| Clone | 9E9 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CD16.2 blockade, in vitro CD16.2 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0379 | InVivoMAb anti-mouse TSLP | 1/5/25/50/100 mg | |||||
| Clone | 28F12 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TSLP neutralization, in vitro TSLP neutralization | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0380 | InVivoMAb anti-human c-Kit (CD117) | 1/5/25/50/100 mg | |||||
| Clone | SR-1 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo c-Kit+ cell depletion, in vitro c-Kit targeting, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0381 | InVivoMAb anti-human GM-CSF | 1/5/25/50/100 mg | |||||
| Clone | BVD2-21C11 | Isotype | Rat IgG2a, κ | ||||
| Application | Immunofluorescence, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0382 | InVivoMAb anti-mouse/human/rat osteopontin (SPP1) | 1/5/25/50/100 mg | |||||
| Clone | MPIIIB10 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo OPN neutralization, in vitro OPN neutralization, Immunohistochemistry (paraffin), Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0383 | InVivoMAb anti-mouse/human/rat PD-L1 | 1/5/25/50/100 mg | |||||
| Clone | 368A.4H1 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-L1 blockade, in vitro PD-L1 blockade, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0384 | InVivoMAb anti-human GM-CSF | 1/5/25/50/100 mg | |||||
| Clone | BVD2-23B6 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro GM-CSF neutralization, ELISA | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0385 | InVivoMAb anti-mouse DKK3 | 1/5/25/50/100 mg | |||||
| Clone | DKK3-4.22 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo DKK3 blocking, in vitro DKK3 blocking, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0386 | InVivoMAb anti-human CD326 (EpCAM) | 1/5/25/50/100 mg | |||||
| Clone | Ber-EP4 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0387 | InVivoMAb anti-mouse/human phosphorylated PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 407.6G12 | Isotype | Mouse IgG2a, κ | ||||
| Application | Western Blot, Flow Cytometry | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0388 | InVivoMAb anti-human CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | BK19.9 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0389 | InVivoMAb anti-canine CD34 | 1/5/25/50/100 mg | |||||
| Clone | 1H6 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (frozen), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0390 | InVivoMAb anti-canine PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | JC071 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro PD-L1 blockade, Functional assays, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0391 | InVivoMAb anti-human MUC16 | 1/5/25/50/100 mg | |||||
| Clone | VK8 | Isotype | Mouse IgG1, κ | ||||
| Application | Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0392 | InVivoMAb anti-mouse myeloperoxidase (MPO) | 1/5/25/50/100 mg | |||||
| Clone | 6G4 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo administration, in vitro administration, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0393 | InVivoMAb anti-mouse myeloperoxidase (MPO) | 1/5/25/50/100 mg | |||||
| Clone | 6D1 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo administration, in vitro administration, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0394 | InVivoMAb anti-mouse IL-25 | 1/5/25/50/100 mg | |||||
| Clone | 2C3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-25 neutralization | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0395 | InVivoMAb anti-mouse/human Mac-2 (Galectin-3) | 1/5/25/50/100 mg | |||||
| Clone | M3/38 (TIB-166) | Isotype | Rat IgG2a, κ | ||||
| Application | Western blot, Immunofluorescence, Immunohistochemistry (paraffin), Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0396 | InVivoMAb anti-human/mouse GRP78 | 1/5/25/50/100 mg | |||||
| Clone | C38 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo GRP78 blockade, in vitro GRP78 blockade, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0397 | InVivoMAb anti-human/mouse GRP78 | 1/5/25/50/100 mg | |||||
| Clone | C107 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo GRP78 targeting, in vitro GRP78 targeting, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0398 | InVivoMAb anti-mouse CD83 | 1/5/25/50/100 mg | |||||
| Clone | Michel-17 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo CD83 blockade, in vitro CD83 blockade, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0399 | InVivoMAb anti-mouse VEGF-A | 1/5/25/50/100 mg | |||||
| Clone | 2G11-2A05 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo VEGF-A neutralization, Western blot | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0400 | InVivoMAb anti-mouse RGMb | 1/5/25/50/100 mg | |||||
| Clone | 307.9D1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo RGMb blockade, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IPT060 | ||||||
| BE0401 | InVivoMAb anti-human CEACAM5 | 1/5/25/50/100 mg | |||||
| Clone | 4H11-8 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0402 | InVivoMAb anti-human GPC-2 | 1/5/25/50/100 mg | |||||
| Clone | CT3 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (paraffin), Flow cytometry , ELISA, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0403 | InVivoMAb anti-mouse CD96 | 1/5/25/50/100 mg | |||||
| Clone | 6A6/CD96 | Isotype | Rat IgG2a, λ | ||||
| Application | in vivo blocking of CD96, in vitro blocking of CD96, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0404 | InVivoMAb anti-human GPC3 | 1/5/25/50/100 mg | |||||
| Clone | YP7 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro photoimmunotherapy, in vivo anti-tumor activity, in vivo imaging, in vivo photoimmunotherapy, Flow cytometry , Immunohistochemistry (paraffin), Immunofluorescence, Western blot, Immunoprecipitation, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0405 | InVivoMAb anti-human mesothelin | 1/5/25/50/100 mg | |||||
| Clone | YP218 | Isotype | Rabbit IgG | ||||
| Application | in vitro photoimmunotherapy*, in vivo photoimmunotherapy*, Chimeric antigen receptor construction, Antibody-drug conjugate synthesis*, Functional assays , Immunohistochemistry (paraffin), Flow cytometry, ELISA, *Use of humanized YP218 (see "References") | ||||||
| Recommended | Isotype Control: BE0095 Dilution Buffer: IP0070 | ||||||
| BE0406 | InVivoMAb anti-human CD2 | 1/5/25/50/100 mg | |||||
| Clone | LO-CD2a | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo T cell depletion , in vivo prevention of graft rejection, in vitro inhibition of MLR , Functional assays, Immunohistochemistry (frozen), ELISA | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0407 | InVivoMAb anti-human Fy3 | 1/5/25/50/100 mg | |||||
| Clone | MIMA-29 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo targeting of HOD Ag+ RBCs, in vitro targeting of HOD Ag+ RBCs, Indirect Antiglobulin Test (IAT), Immunohistochemistry (paraffin), Functional assays, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0408 | InVivoMAb anti-human TROP-2 | 1/5/25/50/100 mg | |||||
| Clone | Pr1E11 | Isotype | Mouse IgG1, κ | ||||
| Application | Western blot, Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0409 | InVivoMAb anti-human BRCA1 | 1/5/25/50/100 mg | |||||
| Clone | BR64 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunofluorescence, Western blot, Immunoprecipitation, Electrophoretic mobility shift assays (EMSA) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0410 | InVivoMAb anti-human EphA2 | 1/5/25/50/100 mg | |||||
| Clone | SHM16 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro stimulation of EphA2 signaling, Functional assays , Immunoprecipitation, Flow cytometry, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0411 | InVivoMAb anti-human GC1q R (C1QBP) | 1/5/25/50/100 mg | |||||
| Clone | 60.11 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blockade of gC1q R , in vitro blockade of gC1q R , in vitro functional assays, Flow cytometry, Immunohistochemistry (paraffin), Immunofluorescence , Immunoprecipitation, Western blot, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0412 | InVivoMAb anti-human pan-Glypican | 1/5/25/50/100 mg | |||||
| Clone | HS20 | Isotype | Human IgG1, κ | ||||
| Application | in vivo blocking of Wnt signaling, in vitro blocking of Wnt signaling, Functional assays, ELISA, Flow cytometry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| BE0413 | InVivoMAb anti-rat TCR α/β | 1/5/25/50/100 mg | |||||
| Clone | R73 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo administration | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0414 | InVivoMAb anti-rat TCR γ/δ | 1/5/25/50/100 mg | |||||
| Clone | V65 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo γ/δ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0415 | InVivoMAb anti-rat CD8α | 1/5/25/50/100 mg | |||||
| Clone | OX-8 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CD8+ T cell depletion, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0416 | InVivoMAb anti-human/mouse GRP78 | 1/5/25/50/100 mg | |||||
| Clone | N88 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo administration, Functional assays | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0417 | InVivoMAb anti-rat CD2 | 1/5/25/50/100 mg | |||||
| Clone | OX-34 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD2 blockade, in vitro CD2 blockade, Western blot | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0418 | InVivoMAb anti-rat CD28 | 1/5/25/50/100 mg | |||||
| Clone | JJ316 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo T cell stimulation/activation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0419 | InVivoMAb anti-rat IL-4 | 1/5/25/50/100 mg | |||||
| Clone | OX-81 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-4 neutralization, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0420 | InVivoMAb anti-mouse CD205 (DEC-205) | 1/5/25/50/100 mg | |||||
| Clone | NLDC-145 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo antigen-targeting to DEC-205, in vitro antigen-targeting to DEC-205, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0421 | InVivoMAb anti-chikungunya virus E2 | 1/5/25/50/100 mg | |||||
| Clone | CHK-265 | Isotype | Mouse IgG2c, λ | ||||
| Application | Viral entry and egress inhibition | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0422 | InVivoMAb anti-mouse CD86 (B7-2) | 1/5/25/50/100 mg | |||||
| Clone | 2D10 | Isotype | Rat IgG2b, κ | ||||
| Application | Immunoprecipitation, Flow cytometry, Functional assays | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0423 | InVivoMAb anti-mouse VISTA | 1/5/25/50/100 mg | |||||
| Clone | 8G8 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo stimulation of VISTA signaling | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0424 | InVivoMAb anti-rat CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | WKH203 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro CTLA-4 neutralization, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0425 | InVivoMAb rat IgG2b isotype control, anti-trinitrophenol-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | TNP-4G1 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0426 | InVivoMAb anti-mouse Dendritic Cell Marker (33D1) | 1/5/25/50/100 mg | |||||
| Clone | 33D1 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo depletion of 33D1+ dendritic cell , in vitro depletion of 33D1+ dendritic cell , in vitro Binding assay, Flow cytometry, Immunofluorescence, Immunohistochemistry | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0427 | InVivoMAb anti-West Nile virus NS1 | 1/5/25/50/100 mg | |||||
| Clone | 10NS1 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo protection against WNV infection, In vitro opsonization of WNV infected cells , ELISA, Flow cytometry, Immunoprecipitation , Western blot | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0428 | InVivoMAb anti-mouse CD11b | 1/5/25/50/100 mg | |||||
| Clone | 5C6 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD11b neutralization, in vitro CD11b neutralization, Flow cytometry, Immunofluorescence , Immunohistochemistry, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0429 | InVivoMAb anti-WNV E protein DIII-LR | 1/5/25/50/100 mg | |||||
| Clone | E16 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo protection against WNV infection, In vitro opsonization of WNV infected cells , ELISA, Flow cytometry, Immunoprecipitation , Western blot | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0430 | InVivoMAb anti-WNV E protein DI-DII | 1/5/25/50/100 mg | |||||
| Clone | E53 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo protection against WNV infection , in vitro neutralization of WNV, in vitro blocking of WNV-cell attachment, in vitro opsonization of WNV infected cells, Plaque reduction neutralization tests (PRNT), Antibody-dependent enhancement (ADE), Flow cytometry , ELISA | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0431 | InVivoMAb anti-Zika virus E protein DIII-LR | 1/5/25/50/100 mg | |||||
| Clone | ZV-67 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo inhibition of ZIKV infection, in vitro neutralization of ZIKV, ELISA, Flow cytometry, Western blot , Focus forming assay (FFA) , Focus reduction neutralization test (FRNT), Plaque reduction neutralization test (PRNT) | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0432 | InVivoMAb anti-Dengue virus type 2 E protein DIII | 1/5/25/50/100 mg | |||||
| Clone | DV2-96 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo neutralization of DENV-2, in vitro neutralization DENV-2, ELISA, Flow cytometry, Plaque reduction neutralization tests (PRNT), Antibody-dependent enhancement (ADE) | ||||||
| Recommended | Dilution Buffer: IPT060 | ||||||
| BE0433 | InVivoMAb anti-Eastern equine encephalitis virus E2 protein | 1/5/25/50/100 mg | |||||
| Clone | EEEV-3 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo protection against EEEV, in vitro neutralization of EEEV, Flow cytometry, ELISA, Plasma membrane fusion-from-without (FFWO), Focus reduction neutralization tests (FRNT), Biolayer Interferometry (BLI) | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0434 | InVivoMAb anti-Powassan virus E protein | 1/5/25/50/100 mg | |||||
| Clone | POWV-63 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo protection against POWV, in vitro neutralization of POWV , Antibody Dependent Enhancement (ADE) , Foci reduction neutralization test (FRNT), Flow cytometry, ELISA | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0435 | InVivoMAb anti-Venezuelan equine encephalitis virus E2 protein | 1/5/25/50/100 mg | |||||
| Clone | VEEV-57 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo protection against VEEV, in vitro neutralization of VEEV, Focus reduction neutralization test (FRNT), Plasma membrane fusion-from-without (FFWO), Inhibition of viral attachment on cells, Inhibition of viral egress, ELISA | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IPT060 | ||||||
| BE0436 | InVivoMAb anti-human VISTA | 1/5/25/50/100 mg | |||||
| Clone | GG8 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry-paraffin, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0437 | InVivoMAb anti-Dengue virus type 4 E protein DIII | 1/5/25/50/100 mg | |||||
| Clone | DV4-E88 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo neutralization of DENV-4, in vitro neutralization of DENV-4, Focus reduction neutralization test (FRNT), ELISA , Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0093 Dilution Buffer: IP0070 | ||||||
| BE0438 | InVivoMAb anti-SARS-CoV-2 S protein (RBD) | 1/5/25/50/100 mg | |||||
| Clone | SARS2-38 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo neutralization of SARS-CoV-2 variants, in vitro neutralization of SARS-CoV-2 variants, Focus reduction neutralization test (FRNT), Flow cytometry, ELISA , Inhibition of viral attachment on cells, Focus forming assay (FFA) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0439 | InVivoMAb anti-rat CD4 | 1/5/25/50/100 mg | |||||
| Clone | W3/25 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo down-regulation of surface CD4, in vitro neutralization of CD4, Flow cytometry, Immunohistochemistry (paraffin) , Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0440 | InVivoMAb anti-mouse CXCL10 (IP-10) | 1/5/25/50/100 mg | |||||
| Clone | 1F11 | Isotype | Armenian Hamster IgG | ||||
| Application | in vitro neutralization of CXCL10, in vivo neutralization of CXCL10, in vivo inhibition of T cell recruitment, Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: BE0091 Dilution Buffer: IP0070 | ||||||
| BE0441 | InVivoMAb anti-human IL-10 | 1/5/25/50/100 mg | |||||
| Clone | JES3-19F1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo neutralization of IL-10, in vitro neutralization of IL-10, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Functional assays, Flow cytometry, Western blot, ELISA | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0442 | InVivoMAb anti-rat CD86 (B7-2) | 1/5/25/50/100 mg | |||||
| Clone | OX-48 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro functional assays, Immunoprecipitation , Flow cytometry , Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0443 | InVivoMAb anti-mouse PDGFRα (CD140a) | 1/5/25/50/100 mg | |||||
| Clone | APA5 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PDGFRα, in vitro blocking of PDGFRα, Functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (whole-mount), Flow cytometry, Western blot, ELISA | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0444 | InVivoMAb anti-human/mouse/rat/canine/swine PSMA | 1/5/25/50/100 mg | |||||
| Clone | 3F11 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunohistochemistry (paraffin), Immunofluorescence, Western blot, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0445 | InVivoMAb anti-mouse CD44 | 1/5/25/50/100 mg | |||||
| Clone | KM703 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro functional assays, Flow cytometry, Immunohistochemistry (frozen), Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0446 | InVivoMAb anti-rat CD47 | 1/5/25/50/100 mg | |||||
| Clone | OX-101 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blockade of CD47, in vitro blockade of CD47, Functional assays , Immunohistochemistry (frozen), Flow cytometry, Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0447 | InVivoMAb anti-mouse TREM-2 | 1/5/25/50/100 mg | |||||
| Clone | 178 | Isotype | Rat IgG2a, κ | ||||
| Application | Flow cytometry , ELISA , in vitro TREM-2 blockade , in vivo TREM-2 blockade (see description)* | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0448 | InVivoMAb anti-rat CD90/mouse CD90.1 (Thy1.1) | 1/5/25/50/100 mg | |||||
| Clone | OX-7 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo induction of anti-Thy1 nephritis, Antibody-drug conjugate (ADC) synthesis, in vivo functional assays, in vitro functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry, Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0449 | InVivoMAb anti-mouse CCL5 (RANTES) | 1/5/25/50/100 mg | |||||
| Clone | R6G9 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo neutralization of CCL5, in vitro neutralization of CCL5, Functional assay, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0450 | InVivoMAb anti-mouse CXCL16 (SR-PSOX) | 1/5/25/50/100 mg | |||||
| Clone | 12-81 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo neutralization of CXCL16, in vitro neutralization of CXCL16, Functional assay, Flow cytometry, Immunofluorescence, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
InVivoPlus
研究分野
ターゲット
| BP0001-1 | InVivoPlus anti-mouse CD3ε | 5/25/50/100 mg | |||||
| Clone | 145-2C11 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0003-1 | InVivoPlus anti-mouse CD4 | 5/25/50/100 mg | |||||
| Clone | GK1.5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0065 | ||||||
| BP0003-3 | InVivoPlus anti-mouse CD4 | 5/25/50/100 mg | |||||
| Clone | YTS 177 | Isotype | Rat IgG2a | ||||
| Application | in vivo blockade of CD4+ T-cell responses, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0004-1 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | 53-6.7 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0065 | ||||||
| BP0012 | InVivoPlus anti-mouse CD25 (IL-2Rα) | 5/25/50/100 mg | |||||
| Clone | PC-61.5.3 | Isotype | Rat IgG1, λ | ||||
| Application | in vivo regulatory T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0016-2 | InVivoPlus anti-mouse CD40 | 5/25/50/100 mg | |||||
| Clone | FGK4.5/FGK45 | Isotype | Rat IgG2a | ||||
| Application | in vivo CD40 activation, in vitro B cell stimulation/activation | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0017-1 | InVivoPlus anti-mouse CD40L (CD154) | 5/25/50/100 mg | |||||
| Clone | MR-1 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0031 | InVivoPlus anti-mouse OX40 (CD134) | 5/25/50/100 mg | |||||
| Clone | OX-86 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo OX40 activation, in vitro OX40 activation, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0032 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | UC10-4F10-11 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0065 | ||||||
| BP0033-2 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | J43 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0065 | ||||||
| BP0036 | InVivoPlus anti-mouse NK1.1 | 5/25/50/100 mg | |||||
| Clone | PK136 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo NK cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| BP0045 | InVivoPlus anti-mouse IL-4 | 5/25/50/100 mg | |||||
| Clone | 11B11 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0050 | InVivoPlus anti-mouse IL-10R (CD210) | 5/25/50/100 mg | |||||
| Clone | 1B1.3A | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western Blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IPT065 | ||||||
| BP0051 | InVivoPlus anti-mouse IL-12 p40 | 5/25/50/100 mg | |||||
| Clone | C17.8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0055 | InVivoPlus anti-mouse IFNγ | 5/25/50/100 mg | |||||
| Clone | XMG1.2 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IFNγ neutralization, in vitro IFNγ neutralization, ELISPOT, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IPT080 | ||||||
| BP0057 | InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β | 5/25/50/100 mg | |||||
| Clone | 1D11.16.8 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0058 | InVivoPlus anti-mouse TNFα | 5/25/50/100 mg | |||||
| Clone | XT3.11 | Isotype | Rat IgG1 | ||||
| Application | in vivo TNFα neutralization, in vitro TNFα neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0080 | ||||||
| BP0060 | InVivoPlus anti-mouse VEGFR-2 | 5/25/50/100 mg | |||||
| Clone | DC101 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0061 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | 2.43 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0063 | InVivoPlus anti-mouse GITR | 5/25/50/100 mg | |||||
| Clone | DTA-1 | Isotype | Rat IgG2b, λ | ||||
| Application | in vivo GITR stimulation | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0066 | InVivoPlus anti-mouse Thy1.2 (CD90.2) | 5/25/50/100 mg | |||||
| Clone | 30H12 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo ILC depletion, in vivo T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0075-1 | InVivoPlus anti-mouse Ly6G | 5/25/50/100 mg | |||||
| Clone | 1A8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0075 | InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1) | 5/25/50/100 mg | |||||
| Clone | RB6-8C5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0079 | InVivoPlus anti-human MHC Class I (HLA-A, HLA-B, HLA-C) | 5/25/50/100 mg | |||||
| Clone | W6/32 | Isotype | Mouse IgG2a, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0065 | ||||||
| BP0083 | InVivoPlus mouse IgG1 isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0085 | InVivoPlus mouse IgG2a isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0086 | InVivoPlus mouse IgG2b isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0087 | InVivoPlus polyclonal Syrian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0088 | InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase | 5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0089 | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0090 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0091 | InVivoPlus polyclonal Armenian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0099 | InVivoPlus recombinant CTLA-4-Ig (hum/hum) | 5/25/50/100 mg | |||||
| Clone | CTLA-4-Ig (hum/hum) | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0101 | InVivoPlus anti-mouse PD-L1 (B7-H1) | 5/25/50/100 mg | |||||
| Clone | 10F.9G2™ | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo PD-L1 blockade, in vitro PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0065 | ||||||
| BP0115 | InVivoPlus anti-mouse TIM-3 (CD366) | 5/25/50/100 mg | |||||
| Clone | RMT3-23 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0117 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | YTS 169.4 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0131 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | 9H10 | Isotype | Syrian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0087 Dilution Buffer: IP0070 | ||||||
| BP0146 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | RMP1-14 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0164 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | 9D9 | Isotype | Mouse IgG2b | ||||
| Application | in vivo CTLA-4 neutralization, Western blot, in vivo intra-tumoral regulatory T cell depletion | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| BP0169 | InVivoPlus anti-mouse 4-1BB (CD137) | 5/25/50/100 mg | |||||
| Clone | LOB12.3 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo activation of 4-1BB | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0080 | ||||||
| BP0173 | InVivoPlus anti-mouse/rat IL-17A | 5/25/50/100 mg | |||||
| Clone | 17F3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-17A neutralization, ELISA | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0174 | InVivoPlus anti-mouse LAG-3 | 5/25/50/100 mg | |||||
| Clone | C9B7W | Isotype | Rat IgG1, κ | ||||
| Application | in vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0175 | InVivoPlus anti-mouse CD71 (TfR1) | 5/25/50/100 mg | |||||
| Clone | R17 217.1.3/TIB-219 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo depletion of CD71+ cells | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0213 | InVivoPlus anti-mouse CSF1R (CD115) | 5/25/50/100 mg | |||||
| Clone | AFS98 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0239 | InVivoPlus anti-mouse 4-1BB (CD137) | 5/25/50/100 mg | |||||
| Clone | 3H3 | Isotype | Rat IgG2a | ||||
| Application | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0241 | InVivoPlus anti-mouse IFNAR-1 | 5/25/50/100 mg | |||||
| Clone | MAR1-5A3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blot | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0273 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | 29F.1A12™ | Isotype | Rat IgG2a | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0274 | InVivoPlus anti-mouse TIGIT | 5/25/50/100 mg | |||||
| Clone | 1G9 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TIGIT stimulation, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0283 | InVivoPlus anti-mouse/human/rat CD47 (IAP) | 5/25/50/100 mg | |||||
| Clone | MIAP410 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CD47 blockade, in vitro CD47 blocking, Immunofluorescence | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0290 | InVivoPlus rat IgG1 isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | TNP6A7 | Isotype | Rat IgG1, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0297 | InVivoPlus human IgG1 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0301 | InVivoPlus human IgG2 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0307 | InVivoPlus anti-mouse CD16/CD32 | 5/25/50/100 mg | |||||
| Clone | 2.4G2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo Fc receptor blocking, Fc receptor blocking, flow cytometry, Fc receptor blocking, immunofluorescence | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0080 | ||||||
| BP0308 | InVivoPlus anti-rat CD4 | 5/25/50/100 mg | |||||
| Clone | OX-38 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| BP0310 | InVivoPlus anti-mouse VISTA | 5/25/50/100 mg | |||||
| Clone | 13F3 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of VISTA signaling, in vitro blocking of VISTA signaling, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0329 | InVivoPlus anti-mouse CD71 (TfR1) | 5/25/50/100 mg | |||||
| Clone | 8D3 | Isotype | Rat IgG2a | ||||
| Application | in vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0356 | InVivoPlus anti-mouse CD20 | 5/25/50/100 mg | |||||
| Clone | MB20-11 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo B cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0366 Dilution Buffer: IP0070 | ||||||
| BP0366 | InVivoPlus mouse IgG2c isotype control, anti-dengue virus | 5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
Isotype Control
| BE0083 | InVivoMAb mouse IgG1 isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0085 | InVivoMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0086 | InVivoMAb mouse IgG2b isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0087 | InVivoMAb polyclonal Syrian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0088 | InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase | 1/5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0089 | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol | 1/5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0090 | InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0091 | InVivoMAb polyclonal Armenian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0092 | InVivoMAb polyclonal human IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal human IgG | Isotype | Human IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0093 | InVivoMAb polyclonal mouse IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal mouse IgG | Isotype | Mouse IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0094 | InVivoMAb polyclonal rat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rat IgG | Isotype | Rat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0095 | InVivoMAb polyclonal rabbit IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rabbit IgG | Isotype | Rabbit IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0130 | InVivoMAb polyclonal goat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal goat IgG | Isotype | Goat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0260 | InVivoMAb Armenian hamster IgG isotype control, anti-glutathione S-transferase | 1/5/25/50/100 mg | |||||
| Clone | PIP | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0297 | InVivoMAb human IgG1 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0301 | InVivoMAb human IgG2 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0366 | InVivoMAb mouse IgG2c isotype control, anti-dengue virus | 1/5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0369 | InVivoMAb polyclonal llama IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal llama IgG | Isotype | Llama IgG | ||||
| Recommended | Dilution Buffer: - | ||||||
| BE0425 | InVivoMAb rat IgG2b isotype control, anti-trinitrophenol-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | TNP-4G1 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0083 | InVivoPlus mouse IgG1 isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0085 | InVivoPlus mouse IgG2a isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0086 | InVivoPlus mouse IgG2b isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0087 | InVivoPlus polyclonal Syrian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0088 | InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase | 5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0089 | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0090 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0091 | InVivoPlus polyclonal Armenian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0290 | InVivoPlus rat IgG1 isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | TNP6A7 | Isotype | Rat IgG1, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0297 | InVivoPlus human IgG1 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0301 | InVivoPlus human IgG2 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0366 | InVivoPlus mouse IgG2c isotype control, anti-dengue virus | 5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP047 | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP048 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP049 | RecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme | 1 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP147 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP148 | RecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP149 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP150 | RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP152 | RecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP152 | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP156 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP156 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP160 | RecombiMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP160 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP161 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP161 | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP169 | RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP169 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP171 | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP173 | RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP174 | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP179 | RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP180 | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG2, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP181 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP183 | RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Armenian Hamster IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
Ready Tag
| RT0263 | ReadyTag anti-c-myc | 1/5/25 mg | |||||
| Clone | 9E10 | Isotype | Mouse IgG1 | ||||
| Application | Western blot, ELISA, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0264 | ReadyTag anti-GST | 1/5/25 mg | |||||
| Clone | F50-3D12.2 | Isotype | Mouse IgG1 | ||||
| Application | Western blot | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0265 | ReadyTag anti-GFP | 1/5/25 mg | |||||
| Clone | F56-6A1.2.3 | Isotype | Mouse IgG2b | ||||
| Application | Western blot, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0266 | ReadyTag anti-6-His | 1/5/25 mg | |||||
| Clone | 6-His | Isotype | Mouse IgG1 | ||||
| Application | Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0267 | ReadyTag anti-OVA | 1/5/25 mg | |||||
| Clone | F2-3.58 | Isotype | Mouse IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0268 | ReadyTag anti-HA | 1/5/25 mg | |||||
| Clone | 12CA5 | Isotype | Mouse IgG2b | ||||
| Application | ELISA, Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0269 | ReadyTag anti-DDDDK | 1/5/25 mg | |||||
| Clone | AP1501 | Isotype | Mouse IgG2b | ||||
| Application | Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
InVivoPure Dilution Buffer
| IP0065 | InVivoPure pH 6.5 Dilution Buffer | 50 ml | |||||
| IP0070 | InVivoPure pH 7.0 Dilution Buffer | 50 ml | |||||
| IP0080 | InVivoPure pH 8.0 Dilution Buffer | 50 ml | |||||
| IPT060 | InVivoPure pH 6.0T Dilution Buffer | 50 ml | |||||
| IPT065 | InVivoPure pH 6.5T Dilution Buffer | 50 ml | |||||
| IPT080 | InVivoPure pH 8.0T Dilution Buffer | 50 ml | |||||
InVivoSIM
| SIM0001 | InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Adalimumab | Isotype | Human IgG1 | ||||
| Application | in vitro TNFα neutralization, in vitro functional assay, Flow Cytometry, ELISA, Immunofluoresence, Immunoprecipitation, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0002 | InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Cetuximab | Isotype | Human IgG1 | ||||
| Application | in vitro EGFR2+ cell depletion (ADCC assay), in vitro functional assay, EGFR blockade, in vivo imaging, Immunohistochemistry (frozen), Immunofluorescence, Flow Cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0003 | InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Nivolumab | Isotype | Human IgG4 | ||||
| Application | in vitro PD-1 neutralization, in vivo blocking of PD-1/PD-L signaling, in vitro functional assay, in vivo functional assay, Flow Cytometry, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0004 | InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ipilimumab | Isotype | Human IgG1 | ||||
| Application | in vitro CTLA-4 neutralization, in vivo CTLA-4 neutralization, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0005 | InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Trastuzumab | Isotype | Human IgG1 | ||||
| Application | in vitro HER2+ cell depletion (ADCC assay), Antibody-drug conjugate synthesis, in vitro functional assays, in vivo functional assays, Flow Cytometry, ELISA, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0006 | InVivoSIM anti-human TNFα (Infliximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Infliximab | Isotype | Human IgG1 | ||||
| Application | in vitro TNFα neutralization , in vitro functional assay, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0007 | InVivoSIM anti-human VEGF (Bevacizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Bevacizumab | Isotype | Human IgG1 | ||||
| Application | VEGF neutralization, Flow Cytometry, ELISA, Immunoprecipitation, Western Block | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0008 | InVivoSIM anti-human CD20 (Rituximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Rituximab | Isotype | Human IgG1 | ||||
| Application | in vivo functional assay, in vitro functional assay, in vitro CD20+ cell depletion (ADCC assay), Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0009 | InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Atezolizumab | Isotype | Human IgG1 | ||||
| Application | in vivo PD-L1 blockade, Flow Cytometry, Western Blot | ||||||
| Recommended | Isotype Control: CP171 Dilution Buffer: IP0070 | ||||||
| SIM0010 | InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Pembrolizumab | Isotype | Human IgG4 | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro blocking of PD-1/PD-L signaling, in vitro functional assay | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0011 | InVivoSIM anti-human C5 (Eculizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Eculizumab | Isotype | Human IgG4 | ||||
| Application | Inhibition of the activation of C5, Functional assays, ELISA, Immunoprecipitation | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0012 | InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ramucirumab | Isotype | Human IgG1 | ||||
| Application | Functional assays, Immunohistochemistry, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0013 | InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Secukinumab | Isotype | Human IgG1 | ||||
| Application | in vitro IL-17A neutralization, Functional assays, Immunofluorescence, Immunohistochemistry, Flow Cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0014 | InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tocilizumab | Isotype | Human IgG1 | ||||
| Application | Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0015 | InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Relatlimab | Isotype | Human IgG4, κ | ||||
| Application | ELISA | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0016 | InVivoSIM anti-human IgE (Omalizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Omalizumab | Isotype | Human IgG1, κ | ||||
| Application | IgE neutralization, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0017 | InVivoSIM anti-human NGF (Tanezumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tanezumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo NGF neutralization, ELISA | ||||||
| Recommended | Isotype Control: BP0301 Dilution Buffer: IP0070 | ||||||
| SIM0018 | InVivoSIM anti-human integrin α4β1 (VLA-4) | 1/5/25/50/100 mg | |||||
| Clone | Natalizumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0092 Dilution Buffer: IP0070 | ||||||
| SIM0019 | InVivoSIM anti-human HER2 (Pertuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Pertuzumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Neutralization | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0020 | InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ustekinumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0021 | InVivoSIM anti-human PD-L1 (Avelumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Avelumab | Isotype | Human IgG1, λ | ||||
| Application | in vitro functional assay, in vitro PD-L1 blockade, ELISA | ||||||
| Recommended | Isotype Control: CP169 Dilution Buffer: IP0070 | ||||||
| SIM0022 | InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Anifrolumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Western blot, ELISA | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0023 | InVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Dupilumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0024 | InVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Vedolizumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP149 Dilution Buffer: IP0070 | ||||||
| SIM0025 | InVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Guselkumab | Isotype | Human IgG1, λ | ||||
| Application | IL-23p19 neutralization, Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP169 Dilution Buffer: IP0070 | ||||||
| SIM0026 | InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Zolbetuximab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0027 | InVivoSIM anti-human PD-L1 (Durvalumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Durvalumab | Isotype | Human IgG1, κ | ||||
| Application | ELISA, Flow Cytometry, Western Blot, Functional assays | ||||||
| Recommended | Isotype Control: CP149 Dilution Buffer: IP0070 | ||||||
| SIM0028 | InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Denosumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Flow Cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0029 | InVivoSIM anti-human IL-17A (Ixekizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ixekizumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, ELISA, Immunofluorescence, Flow Cytometry, Western blot | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0030 | InVivoSIM anti-human IL-6 (Siltuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Siltuximab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0031 | InVivoSIM anti-human nectin-4 (Enfortumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Enfortumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0032 | InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Lecanemab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0033 | InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tiragolumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0297 Dilution Buffer: IP0070 | ||||||
| SIM0034 | InVivoSIM anti-human CD38 (Daratumumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Daratumumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0035 | InVivoSIM anti-human CD25 (IL-2Rα) (Daclizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Daclizumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP173 Dilution Buffer: IP0070 | ||||||
| SIM0036 | InVivoSIM anti-human TSLP (Tezepelumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tezepelumab | Isotype | Human IgG2, λ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: BP0301 Dilution Buffer: IP0070 | ||||||
| SIM0037 | InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Cemiplimab | Isotype | Human IgG4, κ | ||||
| Application | Blocking of PD-1/PD-L signaling, Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0038 | InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tislelizumab | Isotype | Human IgG4, κ | ||||
| Application | Blocking of PD-1/PD-L signaling, Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP183 Dilution Buffer: IP0070 | ||||||
| SIM0039 | InVivoSIM anti-human CEACAM5 (Labetuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Labetuzumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0040 | InVivoSIM anti-human mesothelin (Amatuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Amatuximab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0041 | InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Elotuzumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0042 | InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tralokinumab | Isotype | Human IgG4, λ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP181 Dilution Buffer: IP0070 | ||||||
| SIM0043 | InVivoSIM anti-human TIM-3 (Sabatolimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Sabatolimab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0044 | InVivoSIM anti-human IL-1β (Canakinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Canakinumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0045 | InVivoSIM anti-human CD326 (EpCAM) (Edrecolomab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Edrecolomab | Isotype | Mouse IgG2a, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| SIM0046 | InVivoSIM anti-human CTLA-4 (Tremelimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tremelimumab | Isotype | Human IgG2, κ | ||||
| Application | CTLA-4 neutralization, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| SIM0047 | InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Solanezumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Immunohistochemistry (paraffin) | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0048 | InVivoSIM anti-human amyloid beta (Donanemab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Donanemab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0049 | InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Gevokizumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo neutralization of human IL1β, in vitro neutralization of human IL1β, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP180 Dilution Buffer: IP0070 | ||||||
| SIM0050 | InVivoSIM anti-human EGFR (Panitumumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Panitumumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo neutralization of human EGFR, in vitro neutralization of human EGFR, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP180 Dilution Buffer: IP0070 | ||||||
| SIM0051 | InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Sacituzumab | Isotype | Human IgG1, κ | ||||
| Application | in vitro functional assays, in vivo functional assays, Antibody-drug conjugate synthesis, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
RecombiMAb
| CP001 | RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) | 1 mg | |||||
| Clone | 10F.9G2™-CP001 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2b 10F.9G2 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP002 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1 mg | |||||
| Clone | RMP1-14-CP002 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP005 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1 mg | |||||
| Clone | 29F.1A12™-CP005 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP006 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1 mg | |||||
| Clone | 9D9-CP006 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP007 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1 mg | |||||
| Clone | 9D9-CP007 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| CP008 | RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG) | 1 mg | |||||
| Clone | 9D9-CP008 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP013 | RecombiMAb anti-mouse LAG-3 (D265A) | 1 mg | |||||
| Clone | C9B7W-CP013 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot* *Reported for the original rat IgG1 C9B7W antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP014 | RecombiMAb anti-mouse LAG-3 | 1 mg | |||||
| Clone | C9B7W-CP014 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot* *Reported for the original rat IgG1 C9B7W antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP017 | RecombiMAb anti-mouse OX40 (CD134) | 1 mg | |||||
| Clone | OX86-CP017 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo OX40 activation*, in vitro OX40 activation*, Western blot* *Reported for the original rat IgG1 OX-86 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP018 | RecombiMAb anti-mouse OX40 (CD134) (LALA-PG) | 1 mg | |||||
| Clone | OX86-CP018 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo OX40 activation*, in vitro OX40 activation*, Western blot* *Reported for the original rat IgG1 OX-86 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP025 | RecombiMAb anti-mouse CD16/CD32 | 1 mg | |||||
| Clone | 2.4G2-CP025 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo Fc receptor blocking*, Fc receptor blocking, flow cytometry*, Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP026 | RecombiMAb anti-mouse CD16/CD32 (LALA-PG) | 1 mg | |||||
| Clone | 2.4G2-CP026 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo Fc receptor blocking*, Fc receptor blocking, flow cytometry*, Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP027 | RecombiMAb anti-mouse GITR (D265A) | 1 mg | |||||
| Clone | DTA-1-CP027 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP028 | RecombiMAb anti-mouse GITR | 1 mg | |||||
| Clone | DTA-1-CP028 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP029 | RecombiMAb anti-mouse GITR (LALA-PG) | 1 mg | |||||
| Clone | DTA-1-CP029 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP031 | RecombiMAb anti-mouse GITR (LALA-PG) | 1 mg | |||||
| Clone | DTA-1-CP031 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP049 Dilution Buffer: IP0070 | ||||||
| CP032 | RecombiMAb anti-mouse CD40L (CD154) (D265A) | 1 mg | |||||
| Clone | MR-1-CP032 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP033 | RecombiMAb anti-mouse CD40L (CD154) | 1 mg | |||||
| Clone | MR-1-CP033 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP034 | RecombiMAb anti-mouse CD40L (CD154) (LALA-PG) | 1 mg | |||||
| Clone | MR-1-CP034 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP038 | RecombiMAb anti-mouse 4-1BB (CD137) (LALA-PG) | 1 mg | |||||
| Clone | LOB12.3-CP038 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo activation of 4-1BB* *Reported for the original rat IgG1 LOB12.3 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP039 | RecombiMAb anti-mouse 4-1BBL (CD137L) (D265A) | 1 mg | |||||
| Clone | TKS-1-CP039 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP040 | RecombiMAb anti-mouse 4-1BBL (CD137L) | 1 mg | |||||
| Clone | TKS-1-CP040 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP041 | RecombiMAb anti-mouse 4-1BBL (CD137L) (LALA-PG) | 1 mg | |||||
| Clone | TKS-1-CP041 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP042 | RecombiMAb anti-mouse CD28 | 1 mg | |||||
| Clone | D665-CP042 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation* *Reported for the original mouse IgG1 D665 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP043 | RecombiMAb anti-mouse CD28 (LALA-PG) | 1 mg | |||||
| Clone | D665-CP043 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation* *Reported for the original mouse IgG1 D665 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP044 | RecombiMAb anti-mouse ICOSL (CD275) (D265A) | 1 mg | |||||
| Clone | HK5.3-CP044 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP045 | RecombiMAb anti-mouse ICOSL (CD275) | 1 mg | |||||
| Clone | HK5.3-CP045 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP046 | RecombiMAb anti-mouse ICOSL (CD275) (LALA-PG) | 1 mg | |||||
| Clone | HK5.3-CP046 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP047 | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP048 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP049 | RecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme | 1 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP127 | RecombiMAb anti-mouse CD4 | 1/5/25/50/100 mg | |||||
| Clone | GK1.5-CP127 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion*, Flow cytometry*, Western blot* *Reported for the original rat IgG2b GK1.5 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0065 | ||||||
| CP128 | RecombiMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | 2.43-CP128 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion*, Western blot* *Reported for the original rat IgG2b 2.43 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| CP129 | RecombiMAb anti-mouse Ly6G | 1/5/25/50/100 mg | |||||
| Clone | 1A8-CP129 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo neutrophil depletion*, in vivo MDSC depletion*, Immunofluorescence*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, Flow cytometry* *Reported for the original rat IgG2a 1A8 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP130 | RecombiMAb anti-mouse CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | R17 217.1.3-CP130 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo depletion of CD71+ cells* *Reported for the original rat IgG2a R17 217.1.3 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP131 | RecombiMAb anti-mouse CSF1R (CD115) | 1/5/25/50/100 mg | |||||
| Clone | AFS98-CP131 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo macrophage depletion*, in vitro CSF1R neutralization*, in vivo monocyte depletion*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a AFS98 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP132 | RecombiMAb anti-mouse VEGFR-2 | 1/5/25/50/100 mg | |||||
| Clone | DC101-CP132 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of VEGF/VEGFR-2 signaling*, in vitro blocking of VEGFR signaling*, Western blot* *Reported for the original rat IgG1 DC101 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP133 | RecombiMAb anti-mouse CD40 | 1/5/25/50/100 mg | |||||
| Clone | FGK4.5-CP133 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD40 activation*, in vitro B cell stimulation/activation* *Reported for the original rat IgG2a FGK4.5 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP134 | RecombiMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | YTS 169.4-CP134 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion*, Western blot* *Reported for the original rat IgG2b YTS 169.4 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP135 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | 1/5/25/50/100 mg | |||||
| Clone | RB6-8C5-CP135 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)* *Reported for the original rat IgG2b RB6-8C5 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP146 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | 9H10-CP146 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CTLA-4 neutralization*, in vitro CTLA-4 neutralization*, Western blot, *Reported for the original Syrian hamster IgG 9H10 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP147 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP148 | RecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP149 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP150 | RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP151 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP151 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP150 Dilution Buffer: IP0070 | ||||||
| CP152 | RecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP152 | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP153 | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP153 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP150 Dilution Buffer: IP0070 | ||||||
| CP154 | RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP154 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a 10F.9G2™ antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP155 | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP155 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: CP156 Dilution Buffer: IP0070 | ||||||
| CP156 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP156 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP157 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP157 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP158 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP158 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP159 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP159 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP160 | RecombiMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP160 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP161 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP161 | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP162 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP162 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP168 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP168 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP169 | RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP169 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP171 | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP172 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | 1/5/25/50/100 mg | |||||
| Clone | RB6-8C5-CP172 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)* *Reported for the original rat IgG2b RB6-8C5 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| CP173 | RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP174 | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP178 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP178 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP179 | RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP180 | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG2, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP181 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP182 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP182 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original hybridoma expressed RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| CP183 | RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Armenian Hamster IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
パンフレット
Cancer
癌研究用の抗体
Immunology
免疫学研究用の抗体
Neuroscience
神経科学研究用の抗体
Biosimilars
研究用グレードのバイオシミラーモノクローナル抗体
Depletion Antibodies
マウス免疫細胞を特異的に除去する抗体
Cytokine and Chemokines
サイトカインとそのレセプターを中和・検出する抗体
CD Markers
CDマーカーを標的とする抗体
Tumor Specific Antigens
腫瘍特異的抗原を標的とする抗体
Cell Adhesion and Migration
細胞遊走や細胞接着に関わるタンパク質をブロッキング・検出する抗体
25-Year Anniversary Brochure
Bio X Cell社の全般情報に関するパンフレット
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.
info@tokyofuturestyle.com
TEL：029-851-9222 FAX：029-851-9220
